Meeting Program

ISPOR 18th Annual International MeetingMay 18-22, 2013 Sheraton New Orleans New Orleans, LA, USA

PROGRAM AND SCHEDULE OF EVENTS

ISPOR 18th Annual International MeetingMay 18-22, 2013 • Sheraton New Orleans, New Orleans, LA, USA

PROGRAM AND SCHEDULE OF EVENTS

SATURDAY, MAY 18 8:00AM-5:00PM PRE-MEETING SHORT COURSES Short Course registration required

(Lunch – Attendees on their own See page 15 for Short Course descriptions)

5:15PM-6:15PM EDUCATIONAL SYMPOSIUM Gallery (1st Floor)

OLD WINE IN NEW BOTTLES: DO COMPARATIVE EFFECTIVENESS AND PATIENT-CENTERED OUTCOMES RESEARCH REPRESENT A NEW PARADIGM IN HEALTH RESEARCH? Sponsored by ICON

SUNDAY, MAY 19 8:00AM-5:00PM PRE-MEETING SHORT COURSES Short Course registration required

Lunch – Attendees on their own

3:15PM-5:15PM ISPOR IN ACTION Grand Ballroom A (5th Floor)ISPOR group leaders report on recent activities, all attendees welcome.

3:15PM-3:20PM WELCOME & OVERVIEWDeborah Marshall, PhD, MHSA, 2012-2013 ISPOR President Marilyn Dix Smith, RPh, PhD, ISPOR Executive Director

3:20PM-3:40PM ISPOR CONSORTIUM/NETWORKS Asia Consortium: Surachat Ngorsuraches, PhD, RPh Latin America Consortium: Gabriela Tannus Araújo, MBA, MSc Central & Eastern European Network: Vitaly Omelianovskiy, MD, PhD

3:40PM-4:10PM ISPOR COUNCILS Student Council Faculty Advisory Council: Karen Rascati, RPh, PhD Student Council: Emily Reese, MPH Institutional Council: John O’Donnell, PhD, MA Health Science Policy Council: Lou Garrison, PhD Health Technology Assessment Council: Finn Borlum Kristensen, MD, PhD

4:10PM-4:45PM ISPOR HEALTH SCIENCE GOOD PRACTICES TASK FORCESBudget Impact Analysis Good Practices II Task Force: Sean Sullivan, PhD Conjoint Analysis – Statistical Analysis, Results & Conclusions Good Research Practices Task Force: Brett Hauber, PhD Health Economic Evaluation Publication Guidelines – CHEERS Good Reporting Practices Task Force: Don Husereau, BSc Pharm, MSc Clinician-Reported Outcomes (ClinROs) Good Measurement Practices Task Force: John Powers, MD, FACP, FIDSA Mixed Modes to Collect Patient-Reported Outcomes (PRO) Data in Clinical Trials Task Force: Sonya Eremenco, MA Outcomes Research Methodology Matrix Task Force: Ansgar Hebborn, PhD

4:45PM-5:10PM ISPOR SPECIAL INTEREST GROUPS (SIG) Health Outcomes Metrics SIG: David Vanness, PhD Health Technology Assessment SIG: Annie Chicoye, PhD Medication Adherence and Persistence (MAP) SIG: John Zeber, PhD, MHA Oncology SIG: Kathy Schulman, MA Rare Disease SIG: Nadia Naaman

5:10PM-5:15PM OPEN DISCUSSION & CLOSING REMARKS

5:15PM-6:15PM EDUCATIONAL SYMPOSIUM Gallery (1st Floor)

ASSESSING THE EVIDENCE FOR BETTER PATIENT CARE: SYNTHESIZING THE BODY OF EVIDENCE – A TOOL FOR FORMULARY DECISION MAKINGAn AMCP-ISPOR-NPC CER Collaborative Initiative Sponsored by the National Pharmaceutical Council


PROGRAM AND SCHEDULE OF EVENTS: SUNDAY, MAY 19 & MONDAY, MAY 206:30PM-7:30PM EDUCATIONAL SYMPOSIUM Gallery (1st Floor)

ANALYZE THIS: GETTING THE RIGHT DATA FOR RESEARCH AND EVIDENCE GENERATIONSponsored by Optum

6:30PM-8:30PM ISPOR STUDENT RESEARCH COMPETITION Grand Ballroom D (5th Floor)The Student Research Competition, now in its 8th year, is a quiz competition featuring teams from ISPOR Student Chapters. Questions are from the ISPOR Book of Terms and ISPOR Good Practices for Outcomes Research, 17 teams will participate this year. The top three winning teams receive cash prize for their ISPOR Student Chapter, sponsored by ISPOR.

8:30PM-9:30PM ISPOR STUDENT & FACULTY ADVISOR COUNCIL ICEBREAKER RECEPTION Grand Ballroom E (5th Floor)Reception co-sponsored by: ZRx Outcomes Research, Archimedes, and Health Utilities Inc.

MONDAY, MAY 20 7:15AM-8:15AM EDUCATIONAL SYMPOSIUM Bayside (4th Floor)

MULTI-CRITERIA DECISION MAKING IN AMERICA: SEA CHANGE OR NATURAL EVOLUTION?Sponsored by LASER ANALYTICA

8:30AM-2:15PM RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I Napoleon Ballroom (3rd Floor)

8:30AM-10:30AM WELCOME & FIRST PLENARY SESSION Grand Ballroom (5th Floor)

WELCOME & PRESIDENTIAL ADDRESSDeborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

MEETING PROGRAM OVERVIEWLaurie B. Burke, MPH, RPh, Program Committee Co-Chair and Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USADonald L. Patrick, PhD, MSPH, Program Committee Co-Chair, Professor, Department of Health Services, and Director, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

ISPOR 2013 AVEDIS DONABEDIAN OUTCOMES RESEARCH LIFETIME ACHIEVEMENT AWARDPresented by: Sean D. Sullivan, PhD, Chair, ISPOR Avedis Donabedian Lifetime Achievement Award in Health Outcomes Committee, and Stergachis Family Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USAAWARDEE: Josephine A. Mauskopf, PhD, MHA, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA

FIRST PLENARY SESSION: FINDING THE PATIENT IN HEALTH RESEARCH & POLICYThe new buzz words are ‘patient-centered’ and ‘patient-focused.’ Why is the focus on the patient? Why wasn’t the focus on the patient before now? What is being done differently to truly focus on the patient in health care delivery and health technology (drug) development? During this session, steps for assuring the patient is the focus of effectiveness research and drug development will be presented from the perspective of the FDA, PCORI (Patient-Centered Outcomes Research Institute) and a patient. The new FDA patient-focused drug development program will be discussed as well as the PCORI effectiveness research agenda. In addition, the definition of patient-centered outcomes, and its use by these organizations will be explored. An ISPOR member (a patient) will describe her perspective on patient-centered outcomes and the U.S. health care system.Moderator: Laurie B. Burke, MPH, RPh, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

WHAT DOES “PATIENT-CENTERED OUTCOMES” MEAN?Speaker: Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services, University of Washington, Seattle, WA, USA

FDA’S PROGRAMS TO INCREASE PATIENT FOCUS IN THE DRUG DEVELOPMENT PROCESSSpeaker: Theresa Mullin, PhD, Director, Office of Planning and Informatics, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

Marshall

Burke Patrick

Mauskopf

Burke

Patrick


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 20PCORI’S PROGRAMS TO ASSURE THE PATIENT IS THE CENTER OF EFFECTIVENESS RESEARCHSpeaker: Joe V. Selby, MD, MPH, Executive Director, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

THE PATIENT – WHAT OUTCOMES ARE IMPORTANT TO THE PATIENT IN HEALTH CARE?Speaker: The Patient

10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by Analysis GroupCookies sponsored by RTI Health Solutions

11:00AM-12:00PM ISSUE PANELS - SESSION I

CLINICAL OUTCOMES RESEARCH ISSUESIP1: ARE ADMINISTRATIVE CLAIMS DATA BECOMING OBSOLETE? Bayside (4th Floor)Moderator: Marc Berger, MD, Vice President, Real World Data & Analytics, Pfizer, Inc., New York, NY, USA Panelists: David Thompson, PhD, Senior Vice President, Real World & Late Phase Research, Quintiles Outcome, Cambridge, MA, USA; William H. Crown, PhD, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

ECONOMIC OUTCOMES RESEARCH ISSUESIP2: CAN A LIFE-EXTENDING DRUG BE COST-INEFFECTIVE EVEN IF OFFERED FOR FREE? THE CURIOUS ECONOMICS OF COSTS IN ADDED YEARS OF LIFE Nottoway (4th Floor)Moderator: Peter J. Neumann, ScD, Professor & Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Panelists: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Mohan Bala, BS, Head, Oncology Market Access, Sanofi, Cambridge, MA, USA; Joshua T. Cohen, PhD, Associate Professor, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUESIP3: HOW DO WE BALANCE PATIENT VALUE AND PAYER COST IN ONCOLOGY? Grand Ballroom AB (5th Floor)Moderator: Dana Goldman, PhD, Norman Topping Chair in Medicine and Public Policy, Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA Panelists: Peter Bach, MD, MAPP, Director & Attending Physician, Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Darius Lakdawalla, PhD, Professor & Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, University of Southern California, Los Angeles, CA, USA; Joseph Leveque, MD, Vice President, US Medical - Oncology, Bristol-Myers Squibb, Plainsboro, NJ, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUESIP4: HOW CAN COMPARATIVE EFFECTIVENESS RESEARCH PLAY A MEANINGFUL ROLE IN ADDRESSING DISPARITIES IN HEALTH CARE? A MULTI-NATIONAL DIALOGUE Grand Ballroom DE (5th Floor)Moderator: Kathleen E. Hughes, MBA, Vice President, Health Economics and Outcomes Services, Avalere Health LLC, Washington, DC, USA Panelists: Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Antony Morgan, MSc, PhD, FFPH, Associate Director, National Institute for Health and Clinical Excellence (NICE), London, UK; Bernd H. Brüggenjürgen, MD, MPH, Head, Institute for Health Economics, Steinbeis-University Berlin GmbH and Vice Chairman, German Association for Health Sciences and Public Health (DVGPH), Berlin, Germany

IP5: RULES OF ENGAGEMENT IN DRUG DEVELOPMENT: ACTIVATING THE PATIENT VOICE Grand Ballroom C (5th Floor)

Moderator: Eleanor M. Perfetto, PhD, MS, Senior Director, Reimbursement & Regulatory Affairs, Federal Government Relations, Pfizer, Inc., Washington, DC, USA Panelists: Cynthia Bens, BA, Vice President of Public Policy, Alliance for Aging Research, Washington, DC, USA; Myriam Marquez, BA, JD, National Early-Stage Advisor, Alzheimer’s Association, Seattle, WA, USA

12:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION I 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Lunch sponsored by Precision Health Economics

SelbyMullin


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 2012:15PM-1:15PM EDUCATIONAL SYMPOSIUM Grand Ballroom DE (5th Floor)

THE POWER OF REAL-WORLD EVIDENCE (RWE): FILLING THE GAP BETWEEN BASIC RESEARCH AND DECISION MAKINGSponsored by IMS Health

12:15PM-1:15PM ISPOR STUDENT RESEARCH SHOWCASE Grand Ballroom AB (5th Floor)This session will feature four outcomes research studies, conducted by ISPOR student members and presented at the ISPOR 18th Annual International Meeting, which will have a high impact on patient-centered outcomes. A brief summary of the research study and conclusions will be presented and then the impact of the study on patient-centered outcomes will be discussed.Moderators: Eberechukwu Onukwugha, PhD, MS, Assistant Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA; Zeba M. Khan, PhD, RPh, Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA; Charles D. Petrie, PhD, Vice President, Outcomes Research Head, Specialty Care medicines Development Goup, Pfizer, Inc., Groton, CT, USASpeakers: Tarun Bhagnani, MS, Graduate Student, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY, USA; Tamar Bregje Wissing, Master Student, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands; Abdulkhaliq J. Alsalman, MS, PhD candidate, Department of Pharmacotherapy and Outcomes Sciences, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA; Carrie Savage Bennette MPH, PhD Student, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

1:15PM-2:15PM POSTER AUTHOR DISCUSSION HOUR - SESSION I Napoleon Ballroom (3rd Floor)

2:15PM-3:15PM RESEARCH PODIUM PRESENTATIONS - SESSION I[Page numbers refer to Podium Abstracts in Value in Health 16(3)]

CANCER OUTCOMES RESEARCH STUDIES Grand Ballroom AB (5th Floor)Moderator: Manny Papadimitropoulos, PhD, Director, Health Technology Assessment, Emerging Markets, Eli Lilly & Company, Markham, ON, CanadapgA1 CA1 BREAST CANCER PATIENTS RECEIVING GUIDELINE-CONCORDANT ADJUVANT THERAPY REGIMENS HAVE BETTER ALL-CAUSE AND DISEASE-SPECIFIC 2:15PM-2:30PM SURVIVAL: NEW FINDINGS FROM RURAL GEORGIA Lipscomb J1, Guy GP2, Gillespie T3, Goodman M1, Richardson LC2, Ward KC1, 1Emory University, Rollins School of Public Health, Atlanta, GA, USA, 2Centers for

Disease Control and Prevention, Atlanta, GA, USA, 3Emory University School of Medicine, Atlanta, GA, USApgA1 CA2 EVALUATION OF SURVIVAL OUTCOMES IN SELECT FIRST-LINE TREATMENT REGIMENS FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG 2:30PM-2:45PM CANCER PATIENTS Bhor M1, Winfree KB2, Sail K1, Zagar A2, Pohl G2, Dhanda R1, 1McKesson Specialty Health, The Woodlands, TX, USA, 2Eli Lilly and Company, Indianapolis, IN, USApgA1 CA3 TREATMENT PATTERNS AFTER CASTRATION RESISTANT PROSTATE CANCER (CRPC) DIAGNOSIS: A EUROPEAN PHYSICIAN SURVEY2:45PM-3:00PM Pokras SM1, Zyczynski TM2, Lees M3, Jiao X1, Blanchette C1, Powers J4, 1IMS Health, Alexandria, VA, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol-

Myers Squibb, Rueil-Malmaison, France, 4University of Colorado, Denver, Aurora, CO, USApgA1 CA4 THE USE OF TRANSARTERIAL CHEMOEMBOLIZATION FOR TREATING HEPATOCELLULAR CARCINOMA IN THE SEER-MEDICARE POPULATION3:00PM-3:15PM Breunig IM1, Shaya FT1, Hanna NN2, Chirikov VV1, Seal B3, Mullins CD1, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of

Maryland School of Medicine, Baltimore, MD, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA

CONCEPTUAL PAPERS Nottoway (4th Floor)Moderator: Wenhui Wei, PhD, MS, MBA, Director, Evidence-Based Medicine, Sanofi-Aventis, Basking Ridge, NJ, USApgA2 CP1 ADJUSTING FOR INFLATION IN ECONOMIC EVALUATIONS OF HEALTH TECHNOLOGIES: ARE WE DOING IT WRONG?2:15PM-2:30PM Paulden M, University of Toronto, Toronto, ON, CanadapgA2 CP2 THE NOTION OF REPRESENTATIVE LANGUAGES IN THE CONTEXT OF TRANSLATABILITY ASSESSMENT2:30PM-2:45PM Basse SJ, Martin ML, McCarrier KP, Health Research Associates, Inc., Seattle, WA, USApgA2 CP3 PIECEWISE MODELING OF TIME-TO-EVENT DATA WITH FLEXIBLE PARAMETERIZATION OF COVARIATES AND EFFECTS2:45PM-3:00PM Ishak KJ, United BioSource Corporation, Dorval, QC, CanadapgA2 CP4 MEASURING HEALTH OUTCOMES IN THE ABSENCE OF RIGOUR: WILFUL IGNORANCE OR DELIBERATE MALPRACTICE?3:00PM-3:15PM Kind P, University of Leeds, Leeds, UK

HEALTH CARE STUDIES – EXPENDITURE OR REIMBURSEMENT STUDIES Grand Ballroom C (5th Floor)Moderator: Norman V. Carroll, PhD, Professor of Pharmacoeconomics and Health Outcomes, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USApgA2 HC1 ORPHAN DISEASE DRUG COSTS IN THE UNITED STATES: ASSESSMENT OF LAUNCH PRICING TRENDS IN NON-CANCER ORPHAN DISEASES AND THE 2:15PM-2:30PM FUTURE IMPLICATIONS ON HEALTH SYSTEM ACCESS Davis EA1, Schwartz EL2, 1Metabolic Markets LLC, San Clemente, CA, USA, 2PriceSpective LLC, San Diego, CA, USApgA3 HC2 HEALTH CARE EXPENDITURES AND DEPRESSION AMONG ADULTS WITH CANCER2:30PM-2:45PM Pan X1, Sambamoorthi U2, 1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USApgA3 HC3 DISCREPANCIES BETWEEN FDA APPROVAL AND CMS COVERAGE FOR DRUGS AND DEVICES2:45PM-3:00PM Chambers JD, Neumann PJ, Tufts Medical Center, Boston, MA, USApgA3 HC4 HOSPITALIZATION COSTS AND OUTCOMES AMONG ELDERLY CANCER PATIENTS IN THE UNITED STATES3:00PM-3:15PM Khanna R1, Jariwala K2, Bentley JP1, Patel A3, 1University of Mississippi, University, MS, USA, 2University of Mississippi, Oxford, MS, USA, 3Medical Marketing

Economics, LLC, Oxford, MS, USA


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 20HEALTH TECHNOLOGY ASSESSMENT STUDIES Bayside BC (4th Floor)Moderator: Ashish V. Joshi, PhD, Director, Global Health Economics & Outcomes Research, Shire Pharmaceuticals, Wayne, PA, USA pgA3 HT1 INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES2:15PM-2:30PM Nicod E, Kanavos P, London School of Economics and Political Science, London, UKpgA3 HT2 AGENCY AGREEMENT IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS2:30PM-2:45PM Jaksa A, Demb J, Ho YS, Daniel K, Context Matters, Inc., New York, NY, USApgA3 HT3 ISSUES IN THE SELECTION OF COMPARATORS FOR REGULATORY AND HTA SUBMISSIONS2:45PM-3:00PM DeLozier AM1, Murray JF1, Klopchin MN1, Johnston JA1, Grainger D2, 1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company USA /Australia, West

Ryde, AustraliapgA4 HT4 HEALTH TECHNOLOGY ASSESSMENT LANDSCAPE OF BIOSIMILARS – APPROACHES TO EVALUATIONS AND RESULTS3:00PM-3:15PM Andreykiv M1, Dahal D2, 1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Hawthorne, NY, USA

RESEARCH ON METHODS – PATIENT-REPORTED OUTCOMES STUDIES Grand Ballroom DE (5th Floor)Moderator: Timothy Victor, PhD, Vice President, Science & Strategy, Kantar Health, Princeton, NJ, USApgA4 PO1 APPLICATION OF ITEM RESPONSE THEORY IN VALIDATING THE MORISKY MEDICATION ADHERENCE SCALE IN PATIENTS WITH HYPERTENSION2:15PM-2:30PM Gupta S1, Goren A2, 1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USApgA4 PO2 PSYCHOMETRIC PERFORMANCE OF THE NEI VFQ-25: RASCH ANALYSIS OF THE NEI VFQ-25 AS A MEASURE OF PATIENT-REPORTED VISUAL FUNCTION 2:30PM-2:45PM ACROSS FOUR RETINAL DISEASES Petrillo J1, Ferreira A2, Cano S3, Bressler NM4, Lamoureux E5, 1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Novartis Pharma AG, Basel,

Switzerland, 3ScaleReport, Stotfold, UK, 4John Hopkins University School of Medicine, Baltimore, MD, USA, 5University of Melbourne, Melbourne, AustraliapgA4 PO3 THE PAIN ASSESSMENT FOR LOWER BACK IMPACTS (PAL-I): QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF A NEW PATIENT-REPORTED 2:45PM-3:00PM OUTCOME MEASURE FOR THE ASSESSMENT OF IMPACTS OF LOW BACK PAIN Ramasamy A1, Blum SI1, McCarrier KP2, Quintanar-Solares M2, Bushnell DM2, Liedgens H3, Martin ML2, Argoff CE4, Patrick DL5, Wallace MS6, Freynhagen R7,

1Forest Research Institute, Jersey City, NJ, USA, 2Health Research Associates, Inc., Seattle, WA, USA, 3Grünenthal GmbH, Aachen, Germany, 4Albany Medical College, Albany, NY, USA, 5University of Washington, Seattle, WA, USA, 6University of California, San Diego, La Jolla, CA, USA, 7Benedictus Krankenhaus Tutzing, Tutzing, Germany

pgA5 PO4 TRANSLATABILITY ASSESSMENT OF THE YOUTH QUALITY-OF-LIFE INSTRUMENT–WEIGHT MODULE (YQOL-W)3:00PM-3:15PM Conway K1, Patrick DL2, Acquadro C1, Fuller DS3, 1MAPI Research Trust, Lyon, France, 2University of Washington, Seattle, WA, USA, 3MAPI Institute,

Philadelphia, PA, USA

3:15PM-3:45PM BREAK & EXHIBITS VIEWING 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by Analysis GroupCookies sponsored by RTI Health Solutions

3:45PM-7:45PM RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II Napoleon Ballroom (3rd Floor)

3:45PM-4:45PM RESEARCH PODIUM PRESENTATIONS - SESSION II[Page numbers refer to Podium Abstracts in Value in Health 16(3)]

COMPARATIVE EFFECTIVENESS RESEARCH STUDIES Grand Ballroom C (5th Floor)Moderator: Mei Sheng Duh, MPH, ScD, Managing Principal, Analysis Group, Inc., Boston, MA, USApgA5 CE1 DOES COMPARATIVE EFFECTIVENESS RESEARCH INCREASE ECONOMIC EFFICIENCY?3:45PM-4:00PM Samnaliev M, Children’s Hospital Boston, Boston, MA, USApgA5 CE2 RECONCILING VARIATIONS IN PROPENSITY SCORE MATCHING (PSM) ALGORITHMS IN OBSERVATIONAL COMPARATIVE EFFECTIVENESS RESEARCH (OCER)4:00PM-4:15PM Borah BJ, Heien HC, Mayo Clinic, Rochester, MN, USApgA5 CE3 ADVANTAGES OF BAYESIAN ADAPTIVE TRIALS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER): “RE-ADAPT”ING ALLHAT4:15PM-4:30PM Broglio K1, Ishak J2, Mullins CD3, Connor J1, Luce BR2, Davis B4, 1Berry Consultants, Austin, TX, USA, 2United BioSource Corporation, Bethesda, MD, USA,

3University of Maryland School of Pharmacy, Baltimore, MD, USA, 4The University of Texas School of Public Health, Houston, TX, USApgA5 CE4 COMPARATIVE EFFECTIVENESS OF BIOLOGICS FOR THE INDUCTION OF CLINICAL RESPONSE AND REMISSION IN MODERATE TO SEVERE CROHN’S 4:30PM-4:45PM DISEASE: A NETWORK META-ANALYIS (NMA) Tongbram V1, Szydlowski V2, Linnehan J2, 1Oxford Outcomes, Morristown, NJ, USA, 2Oxford Outcomes, Bethesda, MD, USA

INFECTIOUS DISEASE OUTCOMES RESEARCH STUDIES Grand Ballroom DE (5th Floor)Moderator: Ralph Swindle, PhD, Research Fellow, Global Health Outcomes, Eli Lilly & Company, Indianapolis, IN, USApgA6 IN1 INTERVIEWS WITH PATIENTS WITH CHRONIC HEPATITIS C (CHC) VIRUS INFECTION DOCUMENT UNMET NEEDS, CONTENT VALIDITY, AND 3:45PM-4:00PM COMPREHENSION OF PROS FOR CLINICAL TRIALS Blackburn S1, McCool R1, Panter C1, Young V1, Peterson S2, Mitchell L2, Machouf N3, Scott J4, Humphrey L1, 1Adelphi Values, Manchester, UK, 2Janssen Cilag,

Canada, Toronto, ON, Canada, 3L’Actuel Clinic, Montreal, QC, Canada, 4Janssen Global Services, High Wycombe, UK


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 20pgA6 IN2 CLINICAL CHARACTERISTICS AND TREATMENT DURATION AMONG PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION INITIATING DIRECT- 4:00PM-4:15PM ACTING ANTIVIRAL THERAPY IN A LARGE COMMERCIAL INSURANCE DATABASE IN THE UNITED STATES Bonafede MM1, Suthoff ED2, Eynullayeva E1, 1Truven Health Analytics, Cambridge, MA, USA, 2Vertex Pharmaceuticals, Inc., Cambridge, MA, USApgA6 IN3 THE BURDEN OF HCV TO INSURERS IN THE UNITED STATES: TRENDS IN HEALTH CARE RESOURCE UTILIZATION 2002-20124:15PM-4:30PM Simpson KN1, Simpson AN1, Kirbach SE2, Gooch K2, 1Medical University of South Carolina, Charleston, SC, USA, 2Abbott Laboratories, Abbott Park, IL, USApgA6 IN4 DIRECT AND INDIRECT COST BURDEN OF CHRONIC HEPATITIS C INFECTION IN PRIVATELY-INSURED PATIENTS, STRATIFIED BY LIVER DISEASE SEVERITY4:30PM-4:45PM Tandon N1, Reddy KR2, Lefebvre P3, Parisé H3, Laliberté F3, Pilon D3, Duh MS4, Prabhakar A5, Cho M5, Balart LA6, Fastenau J1, 1Janssen Scientific Affairs, LLC,

Titusville, NJ, USA, 2Hospital of the University of Pennsylvania, Philadelphia, PA, USA, 3Groupe d’analyse, Ltée, Montréal, QC, Canada, 4Analysis Group, Inc., Boston, MA, USA, 5Janssen Services, LLC, Titusville, NJ, USA, 6Tulane University Health Sciences Center, New Orleans, LA, USA

MEDICATION ADHERENCE STUDIES Nottoway (4th Floor)Moderator: Marco DiBonaventura, PhD, Director, Health Economics and Outcomes Research, Kantar Health, New York, NY, USApgA6 MA1 IMPACT OF A VALUE-BASED COPAYMENT WAIVER BENEFIT ON MEDICATION ADHERENCE AND SPENDING3:45PM-4:00PM Gibson TB1, Maclean R2, Carls G1, Moore BJ1, Ehrlich ED1, Baigel C2, 1Truven Health Analytics, Ann Arbor, MI, USA, 2Bristol-Myers Squibb, New York, NY, USApgA7 MA2 BEYOND AVERAGE ADHERENCE: TEMPORAL PATTERNS OF MEDICATION ADHERENCE PREDICT HOSPITALIZATION RISK MORE ACCURATELY THAN THE 4:00PM-4:15PM MEDICATION POSSESSION RATIO Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ, Analysis Group, Inc., Boston, MA, USApgA7 MA3 REVISION AND VALIDATION OF THE MEDICATION ADHERENCE REASONS SCALE (MAR –SCALE)4:15PM-4:30PM Unni EJ1, Farris K2, Olson J3, 1Roseman University of Health Sciences College of Pharmacy, South Jordan, UT, USA, 2The University of Michigan, Ann Arbor, MI,

USA, 3Intermountain Medical Center, Murray, UT, USApgA7 MA4 USING LATENT CLASS PROBABILITY ESTIMATION AND RESIDUAL INCLUSION TO ADDRESS CONFOUNDING IN MEDICATION ADHERENCE MODELING4:30PM-4:45PM Slejko JF1, Garrison L2, Willke RJ3, 1University of Washington, Seattle, WA, USA, 2University of Washington School of Pharmacy, Seattle, WA, USA, 3Pfizer

Primary Care, New York, NY, USA

RESEARCH ON METHODS – MODELING STUDIES Bayside BC (4th Floor)Moderator: Peter Sun, PhD, MD, Vice President, Kailo Research Group, Indianapolis, IN, USApgA7 MO1 MODELING FUTURE PREVALENCE OF NEUROLOGICAL CONDITIONS AND DEMAND FOR PHARMACEUTICALS IN THE UNITED STATES3:45PM-4:00PM Gallo P, Dall T, Storm M, Chakrabarti R, IHS, Washington, DC, USApgA7 MO2 REANALYZING CAROTID ARTERY STENOSIS TREATMENT CLINICAL TRIAL RESULTS FROM A BAYESIAN PERSPECTIVE4:00PM-4:15PM Smolen HJ, Medical Decision Modeling Inc., Indianapolis, IN, USApgA8 MO3 APPLIED CONTRIBUTIONS TO THE EQ-5D HEALTH UTILITY INDEX4:15PM-4:30PM Ghushchyan VH1, Sullivan PW2, Libby AM3, 1University of Colorado Anschutz Medical Campus, School of Pharmacy, Aurora, CO, USA, 2Regis University School

of Pharmacy, Denver, CO, USA, 3University of Colorado, Denver, Aurora, CO, USApgA8 MO4 EXAMINING ONTARIO’S UNIVERSAL INFLUENZA IMMUNIZATION PROGRAM WITH A NEW DYNAMIC INFLUENZA MODEL4:30PM-4:45PM Thommes EW1, Bauch CT2, Meier G3, Chit A4, 1GlaxoSmithKline Canada, Mississauga, ON, Canada, 2University of Guelph, Guelph, ON, Canada,

3GlaxoSmithKline Vaccines, King of Prussia, PA, USA, 4(formerly GlaxoSmithKline) Sanofi Pasteur Canada, Toronto, ON, Canada

PATIENT PROTECTION AND AFFORABLE CARE ACT & OTHER HEALTH CARE REFORM STUDIES Grand Ballroom AB (5th Floor)Moderator: Pam Heaton, PhD, Chair of Pharmacy Practice and Administrative Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH, USApgA8 PP1 THE IMPACT OF MASSACHUSETTS HEALTH CARE REFORM ON PATIENT OUTCOMES3:45PM-4:00PM Sulham K, Armstrong S, Abraham J, Garfield S, GfK Bridgehead, Wayland, MA, USApgA8 PP2 THE IMPACT OF PATIENT PROTECTION AND AFFORDABLE CARE ACT REGULATIONS ON DRUG MANUFACTURERS’ MEDICAID MARKET SEGMENT 4:00PM-4:15PM PROFITABILITY Chen T, Cost P, Gaitonde P, HERON Evidence Development LLC, Somerville, NJ, USApgA8 PP3 TRANSFORMATION OF SERVICES AND CARE PATHWAY REDESIGN IN THE NHS: FURTHER REFORMS IN HEALTH POLICY4:15PM-4:30PM Mallinson M, King P, Access Partnership, London, UKpgA9 PP4 MEDICATION UTILIZATION TO ANTIDEPRESSANTS AMONG DUAL ELIGIBLES BEFORE AND AFTER PART D4:30PM-4:45PM Kim JA, Karaca-Mandic P, Blewett L, University of Minnesota, Minneapolis, MN, USA

5:00PM-6:00PM WORKSHOPS - SESSION I

CLINICAL OUTCOMES RESEARCHW1: ECONOMETRIC METHODS FOR ASSESSING TREATMENT-EFFECT HETEROGENEITY Nottoway (4th Floor)Discussion Leaders: Anirban Basu, MS, PhD, Associate Professor, Health Services, University of Washington, Seattle, WA, USA; David Vanness, PhD, Professor, Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA; Donald E. Stull, PhD, Director, Retrospective Data Analysis, RTI Health Solutions, Didsbury, Manchester, UK; David Thompson, PhD, Senior Vice President, Real World & Late Phase Research, Quintiles Outcome, Cambridge, MA, USA

ECONOMIC OUTCOMES RESEARCHW2: LEADING HORSES TO WATER: EXPERIMENTAL ANALYSIS OF CHOICE AND ADHERENCE IN DESIGNING PAY-FOR-PERFORMANCE AND OTHER FINANCIAL-INCENTIVES PROGRAMS Grand Ballroom DE (5th Floor)Discussion Leaders: F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Florian Turk, PhD, Global Head, Health Economics & Outcomes Research, Critical Care Business Franchise, Novartis Pharma AG, Basel, Switzerland; Ateesha F. Mohamed, MA, Senior Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 20HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCHW3: PRESENTING UNCERTAINTY (AND ITS CONSEQUENCES) IN COST EFFECTIVENESS TO BEST INFORM POLICY DECISIONS Bayside BC (4th Floor)Discussion Leaders: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Marta O. Soares, MSc, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Keith Abrams, MSc, PhD, Professor of Medical Statistics, Department of Health Sciences, University of Leicester, Leicester, UK; Sean D. Sullivan, PhD, Stergachis Family Professor & Director, University of Washington, Pharmaceutical Outcomes Research and Policy Program, Seattle, WA, USA

W4: CAPTURING PATIENT AND OBSERVER PERSPECTIVES FOR EVALUATING TREATMENTS FOR PEDIATRIC MENTAL HEALTH CONDITIONS - OPPORTUNITIES AND CHALLENGES Bayside A (4th Floor)Discussion Leaders: Asha Hareendran, PhD, MA, Senior Research Scientist, United BioSource Corporation, London, United Kingdom; Juliana Setyawan, PharmD, MS, PhD, Shire Development LLC, Wayne, PA, USA; Keith Saylor, PhD, Licensed Clinical Psychologist, NeuroScience Inc., Herndon, PA, USA; Elektra Papadopoulos, MD, MPH, Endpoints Reviewer, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

W5: ACCOUNTABLE CARE ORGANIZATION PHARMACEUTICAL READINESS: IS THE GLASS HALF-FULL, HALF-EMPTY, OR DO WE NEED A DIFFERENT GLASS? Grand Ballroom AB (5th Floor)Discussion Leaders: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA; Jerry Penso, MD, MBA, Chief Medical and Quality Officer, American Medical Group Association, Alexandria, VA, USA; Gregory R. Kotzbauer, BA, Project Manager, Health Policy & ACO, The Dartmouth Institute, Lebanon, NH, USA; Marv Feldman, MS, RPh, Managing Principal, Consulting Services Group, Premier Inc., Charlotte, NC, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCHW6: BEST PRACTICES AND PROMISING MODELS FOR PATIENT ENGAGEMENT IN PATIENT-CENTERED RESEARCH Grand Ballroom C (5th Floor)Discussion Leaders: Kathleen W. Wyrwich, PhD, Senior Research Leader, United BioSource Corporation, Bethesda, MD, USA; Sue Sheridan, MIM, MBA, Director of Patient Engagement, Patient-Centered Outcomes Research Institute, Washington, DC, USA; Theresa Mullin, PhD, Director, Office of Planning and Informatics, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Steven I. Blum, MBA, Director, Health Economics and Outcomes Research, Forest Research Institute, Jersey City, NJ, USA

USE OF REAL WORLD DATAW7: FROM OBSERVATION TO PERSONALIZED DECISION SUPPORT – HOW REAL WORLD EVIDENCE CONTRIBUTES TO THE ESTABLISHMENT OF E-SCREENING PROGRAMS Oak Alley (4th Floor)Discussion Leaders: Jacco A. Keja, PhD, Lecturer, IBMG, Erasmus University, Rotterdam, The Netherlands; Gabriel Chodick, PhD, Unit Director, Epidemiology & Database Research Unit, Maccabi Healthcare Services, Tel Aviv, Israel; Fabian Offer, PhD, Co-CEO, Medial Research Ltd, Ramot Hashavim, Israel

6:00PM-6:30PM ISPOR ANNUAL BUSINESS MEETING Nottoway (4th Floor)Call to order: Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR PresidentExecutive Director’s Report: Marilyn Dix Smith, RPh, PhD, ISPOR Executive DirectorTreasurer’s Report: Karen Rascati, RPh, PhD, ISPOR TreasurerAudit Report: Kenneth KC Lee, MPhil, PhD, RPhValue in Health Co-Editors-in-Chief Report: C. Daniel Mullins, PhD and Michael Drummond, PhDValue in Health Regional Issues Co-Editor-in-Chief Report: Bong-min Yang, PhD, Federico Augustovski, MD, MSc, PhD, and Dan Greenberg, PhDISPOR CONNECTIONS Editor-in-Chief Report: David Thompson, PhDMember Open Discussion: ISPOR MembersNew Business: Deborah Marshall, PhD, MHSA

6:00PM-7:45PM EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION II 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Reception sponsored by United BioSource Corporation

6:15PM-7:15PM ISPOR FORUMS - SESSION I

CLINICIAN-REPORTED OUTCOMES (ClinROs): GOOD MEASUREMENT PRACTICES Bayside BC (4th Floor)Task Force members will define which outcome assessments should be considered ClinROs and make recommendations for the evaluation of ClinRO measures to support a labeling claim of treatment benefit. Presented by the ISPOR Clinician-Reported Outcomes (ClinROs) Good Measurement Practices Task ForceModerator & Speaker: John H. Powers, III, MD, FACP, FIDSA, Senior Medical Scientist, Support to Collaborative Clinical Research Branch (CCRB), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH), Bethesda, MD, USA Speakers: Laurie B. Burke, RPh, MPH, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Washington, DC, USA; Donald Patrick, PhD, MSPH, Professor, Department of Health Services & Director, Seattle Quality of Life Group & Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

PRINCIPLES OF GOOD PRACTICE FOR BUDGET IMPACT ANALYSIS Grand Ballroom DE (5th Floor)This forum will discuss updated guidelines for researchers and decision makers performing budget impact analyses or reviewing the results of such analyses in order to deter-mine the affordability of new health care interventions. It will also address the role of health outcomes in assessing the budget impact. Presented by the ISPOR Budget Impact Analysis Good Practices II Task Force


PROGRAM AND SCHEDULE OF EVENTS: MONDAY, MAY 20Moderator: Sean Sullivan, PhD, Stergachis Family Professor & Director, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USASpeakers: Josephine Mauskopf, PhD, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA; J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine & Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ, Canada; Karen Lee, MA, Director, Health Economics, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada; Mark Minchin, MBA, Technical Adviser – PASLU, National Institute for Health and Clinical Excellence, Manchester, UK

CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) Grand Ballroom AB (5th Floor)The task force will present the 24-item CHEERS Statement that provides guidance on the minimum reporting requirements to optimize the reporting of health economic evaluations. Examples and explanations for these recommendations will be included. Presented by the ISPOR Health Economic Evaluation Publication Guidelines Task ForceModerator: Don Husereau, BScPharm, MSc, Adjunct Professor, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada and Senior Scientist, University for Health Sciences, Medical Informatics and Technology, Tirol, Austria Speakers: Andrew H. Briggs, MSc (York), MSc (Oxon), DPhil (Oxon), Associate Editor, Medical Decision Making, Co-Editor, Health Economics and William R Lindsay Chair of Health Economics, Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, Scotland; Chris Carswell, MRPharmS, MSc, Editor, Pharmacoeconomics, Adis International, Auckland, New Zealand; Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

THE STUDENT FORUM: INCORPORATING PATIENT-CENTERED OUTCOMES WITHIN COMPARATIVE EFFECTIVENESS RESEARCH: IMPLICATIONS FOR CLINICAL PRACTICE, HEALTH CARE POLICY, AND STUDENT’S CAREER PATHS Grand Ballroom C (5th Floor)How the integration of patient-centered outcomes in both clinical and comparative effectiveness research will affect patients, pharmacists, providers, and researchers in the coming years will be discussed. Speakers will identify how young researchers can prepare themselves for future opportunities in patient-centered comparative effectiveness research. Presented by the ISPOR Student CouncilModerators: Zeba Khan, PhD, RPh, ISPOR Student Network Advisor and Vice President, Strategic Market Access & Policy, Celgene Corporation, Summit, NJ, USA; Emily Reese, MPH, ISPOR Student Network Chair and Graduate Research Assistant, University of Maryland, Baltimore, MD, USASpeakers: C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA; Eleanor M. Perfetto, PhD, MS, Senior Director, Reimbursement and Regulatory Affairs, Pfizer, Inc., Washington, DC, USA; Danielle Lavallee, PhD, PharmD, Survey Center Senior Manager & Lead Researcher, University of Washington, Seattle, WA USA; Margaret Rothman, PhD, Senior Director, PRO Group, GSM&MA, Janssen Global Services, Washington, GA, USA

HEALTH TECHNOLOGY ACCESS AMONG THE BRICS COUNTRIES: BRAZIL, RUSSIA, INDIA, CHINA, AND SOUTH AFRICA Bayside A (4th Floor)The BRICS countries represent a dynamic arena for the positive implementation of pharmacoeconomics and outcomes research practices, with opportunities and challenges for health technology access for patients. Encompassing nearly three billion people with a combined GDP of US $14.0 trillion as of 2013, the opportunities for innovative technolo-gies to improve health outcomes and quality of life are clear; however, challenges like inequity of health care access, drug/device pricing, government formulary approval, procurement and supply chain logistics, and off-patent label competition all serve as barriers to patient access for new health technologies. This forum will outline the opportuni-ties and challenges for health technology access among the BRICS countries, as well as highlight the importance of these emerging policy trends. Presented by the ISPOR Brazil, Russia, India, China, and South Africa Regional ChaptersModerator & Speaker: Gabriela Tannus, MBA, MSc, President, ISPOR Brazil Chapter and Owner & Health Economics Director, Axia.Bio Consulting, São Paulo, BrazilSpeakers: Madhur Gupta, MD, DM, Technical Officer, Pharmaceuticals, World Health Organization Country Office for India, New Delhi, India; Wen Chen, PhD, President, ISPOR Shanghai Chapter and Professor & Deputy Dean, School of Public Health, Fudan University, Shanghai, China; Vitaly V. Omelianovskiy, MD, PhD, President, ISPOR Russia HTA Chapter, Chairman of the Board, National Center for Technology Assessment in Health Care, and Deputy Director, Center for Monitoring and Clinical & Economic Evaluation, Moscow, Russia; Jacques Snyman, MBChB, MPharm Med, MD, President, ISPOR South Africa Chapter and Clinical Pharmacologist, Agility Global Health Solutions, Pretoria, South Africa

HEALTH CARE DATA IN THE ARABIC-SPEAKING COUNTRIES: CHALLENGES IN COLLECTING, SHARING, AND APPLYING Oak Alley (4th Floor)Pharmacoeconomics and outcomes research require the use of primary data from Randomized Controlled Trials (RCTs) as well as other secondary and real world health care data. The lack of health care data creates a major barrier to the application of pharmacoeconomics and outcomes research in the Arabic-speaking countries. This forum will discuss the challenges in collecting, sharing, and applying data in pharmacoeconomic studies and outcomes research in these countries. Examples of the best strategies to overcome existing barriers to the availability and use of data in pharmacoeconomics and outcomes research will be provided. Speakers will shed light on the challenges and opportunities related to health care data availability and applications in Egypt, Jordan, Qatar, Saudi Arabia, and United Arab Emirates and will emphasize initiatives that need to be taken by the relevant authorities in these countries. Presented by the ISPOR Arabic NetworkModerator & Speaker: Abdulaziz H. Al-Saggabi, MSc, PharmD, President, ISPOR Saudi Arabia Chapter and Director, Drug Policy & Economics Center, National Guard Health Affairs, Riyadh, Kingdom of Saudi ArabiaSpeakers: Manal El-Hamamsy, BSPharm, PhD, Assistant Professor, Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Daoud Al-Badriyeh, PhD, President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics, College of Pharmacy, Qatar University, Doha, Qatar; Mohammed Al-Kelya, PhD, Head, Research Quality Management, King Abdullah International Medical Research Center, Riyadh, Kingdom of Saudi Arabia; Ola G. Al Ahdab Albannay, PhD, PGD, RPh, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates

6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR - SESSION II Napoleon Ballroom (3rd Floor)


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21

TUESDAY, MAY 21 7:15AM-8:15AM EDUCATIONAL SYMPOSIUM Bayside (4th Floor)

THE PROMISE OF PERSONALIZED MEDICINE – “GETTING IT RIGHT THE FIRST TIME”Sponsored by Xcenda

8:30AM-2:15PM RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III Napoleon Ballroom (3rd Floor)

8:30AM-10:30AM WELCOME, AWARDS & SECOND PLENARY SESSION Grand Ballroom (5th Floor)

WELCOMEDeborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

INCOMING PRESIDENTIAL ADDRESSWilliam H. Crown, PhD, 2012-2013 ISPOR President-elect and Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

2013 ISPOR VALUE IN HEALTH PAPER OF THE YEAR AWARDAnnounced by: Michael Drummond, PhD, University of York, Heslington, York, UK, and C. Daniel Mullins, PhD, University of Maryland, Baltimore, MD, USA, Value in Health Co-Editors-in-ChiefAWARDEE: Anna Teytelman, PhD, Software Engineer, Google Inc., New York, NY, USAFor the paper, “Modeling the effects of H1N1 influenza vaccine distribution in the United States” Value Health 2012;15:158-66.

ISPOR SCIENTIFIC AWARDS PRESENTATIONSModerated by: Henry Glick, PhD, Chair, ISPOR Awards Committee and Professor of Medicine, University of Pennsylvania Division of Internal Medicine, Philadelphia, PA, USA

2013 ISPOR AWARD FOR EXCELLENCE IN METHODOLOGY IN PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARDPresented by: Anirban Basu, PhD, Chair, ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research Committee, Associate Professor, Department of Health Services, School of Public Health, and Adjunct Associate Professor, Economics and Pharmaceutical Outcomes Research and Policy Program (PORPP), University of Washington, Seattle, WA; and Faculty Research Fellow, The National Bureau of Economic Research, Cambridge, MA, USAAWARDEE: Ping Wang, PhD, Senior Biostatistician, Global Medical Affairs, Biogen Idec, Weston, MA, USAFor the paper, “Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial” Health Serv Outcomes Res Methodol 2012;12:182–99.

2013 ISPOR AWARD FOR EXCELLENCE IN APPLICATION OF PHARMACOECONOMICS AND HEALTH OUTCOMES RESEARCH AWARDPresented by: Daniel C. Malone, PhD, RPh, Chair, ISPOR Award for Excellence in Application of Pharmacoeconomics and Health Outcomes Research Committee and Professor, College of Pharmacy, and Associate Professor, College of Public Health, University of Arizona, Tucson, Arizona, USAAWARDEE: Marisa E. Domino, PhD, Professor, Health Policy and Management, The University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USAFor the paper, “Does managed care affect the diffusion of psychotropic medications?” Health Econ 2012;21:428-43.

2013 ISPOR BERNIE J. O’BRIEN NEW INVESTIGATOR AWARDPresented by: Shelby Reed, PhD, RPh, Chair, ISPOR Bernie J. O’Brien New Investigator Award Committee, Professor & Assistant Research Professor, Duke Clinical Research Institute, Durham, NC, USAAWARDEE: Jennifer Polinski, MPH, MSc, ScD, Instructor in Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Crown

Marshall

Teytelman

Wang

Domino

Polinski


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21SECOND PLENARY SESSION: FINDING THE PATIENT IN THE DRUG DEVELOPMENT PROCESSDuring the first phases of the drug development process, researchers are focusing on a technology (drug) for treating a disease or disorder at a molecular or mechanism of action level. However, during the technology development process, when is the patient’s well-being actually taken into consideration - Phase II or Phase III or ever? During this session, whether the patient’s well-being ‘is’ or ‘is not’ being considered during the drug development process will be debated from the perspective of a pharmaceutical company, the FDA, and most importantly – the patient. This session will include a pharmaceutical company CMO, a patient advocate, and the FDA.Moderator: Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services, University of Washington, Seattle, WA, USA

THE PATIENT’S WELL-BEING: THE FDA’S PERSPECTIVE ON THE DRUG DEVELOPMENT PROCESSSpeaker: Laurie B. Burke, MPH, RPh, Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

THE PATIENT’S WELL-BEING: AN INDUSTRY PERSPECTIVE ON THE DRUG DEVELOPMENT PROCESSSpeaker: Freda C. Lewis-Hall, MD, FAPA, Executive Vice President & Chief Medical Officer, Pfizer, Inc., New York, NY, USA

THE PATIENT’S WELL-BEING: THE PATIENT’S AND CAREGIVER’S PERSPECTIVE ON THE DRUG DEVEL-OPMENT PROCESSSpeaker: Gail Gibson Hunt, President & CEO, National Alliance for Caregiving, Bethesda, MD, USA

10:30AM-11:00AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by STATinMED ResearchCookies sponsored by RTI Health Solutions

11:00AM-12:00PM ISSUE PANELS - SESSION II

CLINICAL OUTCOMES RESEARCH ISSUESIP6: DO TRIAL DESIGN AND ENDPOINT SELECTION FOR TOMORROW’S CANCER DRUGS INCORPORATE PATIENT-CENTERED MEASURES AND MEET MULTIPLE STAKE-HOLDER NEEDS? Grand Ballroom DE (5th Floor)Moderator: Alexander Warren Bastian, MBA, Principal Consultant, GfK Bridgehead, San Francisco, CA, USA Panelists: Roy D. Baynes, MD, PhD, Senior Vice President, Oncology and Inflammation Therapeutics, Gilead Sciences Inc., Foster City, CA, USA; Christopher-Paul Milne, DVM, MPH, JD, Director of Research, Tufts Center for the Study of Drug Development, Tufts University, Boston, MA, USA; Ron L. Akehurst, BSc, Professor of Health Economics, School of Health and Related Research, University of Sheffield and Member, National Institute for Health and Clinical Excellence (NICE) Diagnostics Committee, Sheffield, UK

ECONOMIC OUTCOMES RESEARCH ISSUESIP7: MODEL OR...ELSE? THE FUTURE OF ENHANCING THE GENERALISABILITY ACROSS LOCATIONS OF ECONOMIC EVALUATIONS Bayside (4th Floor)Moderator: Andrew Briggs, DPhil, MSc, William R. Lindsay Chair of Health Economics, Department of Health Economics & Health Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK Panelists: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington,York, UK; Manuel Antonio Espinoza, MD, PhD, Lecturer, Department of Public Health, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile; Adrian Gheorghe, MSc, Doctoral Researcher, Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK

IP8: CAN BAYESIAN ADAPTIVE CER TRIAL DESIGNS BRIDGE THE NEEDS OF PATIENTS, PAYERS, REGULATORS, AND MANUFACTURERS? Nottoway (4th Floor)Moderator: Jack Ishak, PhD, Director & Senior Research Scientist, Biostatistics and Epidemiology, United BioSource Corporation, Bethesda, MD, USA Panelists: Rachael Fleurence, PhD, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA; Charles E. Barr, MD, MPH, Medical Director, Head of Registries, Medical Affairs, Genentech, Inc., South San Francisco, CA, USA

HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUESIP9: WHEN SHOULD OBSERVATIONAL STUDIES BE USED FOR DECISION MAKING, OR WHEN WILL THE EMPEROR HAVE CLOTHES? Grand Ballroom C (5th Floor)Moderator: Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA Panelists: Jean Slutsky, PA, MSPH, Director, Center for Outcomes and Evidence (COE), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Paul Wallace, MD, Senior Vice President & Director, Center for Comparative Effectiveness, The Lewin Group, Falls Church, VA, USA; Marcus Wilson, PharmD, President, HealthCore, Wilming-ton, DE, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUESIP10: STAKEHOLDER ENGAGEMENT IN PATIENT-CENTERED OUTCOMES RESEARCH: HIGH TOUCH OR HIGH TECH? Grand Ballroom AB (5th Floor)Moderator: Danielle Lavallee, PharmD, PhD, Lead Researcher & Senior Manager, Department of Surgery/Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA Panelists: C. Daniel Mullins, PhD, Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA; Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA; Rafael Alfonso, MD, PhD, Scientific Director, Surgical Outcomes Research Center, University of Washington, Seattle, WA, USA

Hunt

Patrick

Lewis-HallBurke


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 2112:00PM-2:15PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION III 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Lunch sponsored by Abacus International

12:15PM-1:15PM EDUCATIONAL SYMPOSIUM Grand Ballroom DE (5th Floor)

WILLINGNESS TO PAY, ABILITY TO PAY, AND MONEY-EQUIVALENT VALUE: MEASURING AND USING MONETIZED HEALTH BENEFITSSponsored by RTI Health Solutions

1:15PM-2:15PM POSTER AUTHOR DISCUSSION HOUR - SESSION III Napoleon Ballroom (3rd Floor)

2:15PM-3:15PM RESEARCH PODIUM PRESENTATIONS - SESSION III [Page numbers refer to Podium Abstracts in Value in Health 16(3)]

DRUG USE & DISEASE MANAGEMENT STUDIES Grand Ballroom C (5th Floor)Moderator: Jeff J. Guo, PhD, Professor, Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati Medical Center College of Pharmacy, Cincinnati, OH, USApgA9 DU1 TREATING ACUTE HEART FAILURE IN THE ELDERLY: A COMPARISON OF THREE INPATIENT TREATMENT ALTERNATIVES IN THE UNITED STATES2:15PM-2:30PM Gradman AH1, Vekeman F2, Eldar-Lissai A3, Trahey A3, Lacomte P4, Ong SH4, Duh MS3, 1Temple University School of Medicine, Pittsburgh, PA, USA, 2Groupe

d’analyse, Montréal, QC, Canada, 3Analysis Group, Inc., Boston, MA, USA, 4Novartis Pharma AG, Basel, SwitzerlandpgA9 DU2 THE SHORT- AND LONG-TERM IMPACT OF CONSUMER-DRIVEN HIGH DEDUCTIBLE HEALTH PLANS ON MEDICATION USE2:30PM-2:45PM Gibson TB1, Carls G1, Moore BJ1, Ehrlich ED1, Heithoff K2, 1Truven Health Analytics, Ann Arbor, MI, USA, 2Merck & Co, Inc., Whitehouse Station, NJ, USApgA9 DU3 COHORT ANALYSIS ASSESSING MEDICAL AND NON-MEDICAL COST ASSOCIATED WITH OBESITY IN THE WORKPLACE2:45PM-3:00PM Abouzaid S1, Kleinman NL2, Andersen L3, Wang Z1, Powers A1, 1Eisai Inc., Woodcliff Lake, NJ, USA, 2The HCMS Group, Cheyenne, WY, USA, 3HCMS Group,

Cheyenne, WY, USApgA9 DU4 THE ASSOCIATION OF BURN INJURIES AND PSEUDOEPHEDRINE SALES3:00PM-3:15PM Goodin AJ, Perin NR, Freeman PR, Talbert J, Wittmer D, Blumenschein K, University of Kentucky, Lexington, KY, USA

MEDICARE STUDIES Grand Ballroom DE (5th Floor)Moderator: Alex Z. Fu, PhD, Associate Professor, Cancer Prevention and Control Program, Georgetown University, Washington, DC, USApgA10 MD1 IMPACT OF MEDICARE PART D COVERAGE ON HEALTH OUTCOMES IN END-STAGE RENAL DISEASE2:15PM-2:30PM Park H1, Rascati KL1, Lawson KA1, Barner J1, Richards K1, Malone DC2, 1The University of Texas at Austin, Austin, TX, USA, 2University of Arizona, Tucson, AZ,

USApgA10 MD2 SKELETAL-RELATED EVENTS AND MORTALITY AMONG SEER-MEDICARE PATIENTS WITH METASTATIC PROSTATE CANCER: THE IMPLICATIONS OF 2:30PM-2:45PM MEASUREMENT APPROACH Onukwugha E1, Yong C1, Mullins CD1, Seal B2, Hussain A3, 1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bayer HealthCare

Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3University of Maryland School of Medicine, Baltimore, MD, USApgA10 MD3 ASSOCIATION BETWEEN INHALED ANTICHOLINERGICS USE AND ALL-CAUSE MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH 2:45PM-3:00PM RESPIRATORY DISEASES Ajmera MR1, Pan X1, Findley P2, Rust G3, Sambamoorthi U4, 1West Virginia University, Morgantown, WV, USA, 2Rutgers University, New Brunswick, NJ, USA,

3Morehouse School of Medicine, Atlanta, GA, USA, 4West Virginia University School of Pharmacy, Morgantown, WV, USApgA10 MD4 GEOGRAPHIC VARIATION IN LOCAL MEDICARE COVERAGE FOR PART B BIOLOGICS3:00PM-3:15PM Saret CJ, Cangelosi MJ, Chambers JD, Cohen JT, Neumann PJ, Tufts Medical Center, Boston, MA, USA

PRICING STUDIES Grand Ballroom AB (5th Floor)Moderator: Christina Kelton, PhD, MS, Professor of Economics, College of Business, University of Cincinnati, Cincinnati, OH, USApgA10 PR1 PAYER PERSPECTIVES ON DRUG PRICING, COVERAGE, AND REIMBURSEMENT IN OPHTHALMOLOGIC ORPHAN CONDITION IN THE UNITED STATES2:15PM-2:30PM Gavaghan M1, Abraham J1, Pauer L2, 1GfK Bridgehead, Wayland, MA, USA, 2Santen, Inc., Emeryville, CA, USApgA10 PR2 SHORTCOMINGS OF EQ-5D IN A VALUE-BASED PRICING FRAMEWORK2:30PM-2:45PM Tordrup D1, Mossman J2, Kanavos P3, 1London School of Economics, London, UK, 2European Federation of Neurological Associations, Dublin, Ireland, 3London

School of Economics and Political Science, London, UKpgA11 PR3 A CONTINGENT VALUATION SURVEY OF USER FINANCIAL INCENTIVES FOR HEALTH BEHAVIOUR CHANGE2:45PM-3:00PM Meads DM, McCabe C, Camidge DC, Hill KM, House AO, Hulme CT, University of Leeds, Leeds, UKpgA11 PR4 THE IMPACT OF GENERIC DRUG POLICY ON DRUG PRICING3:00PM-3:15PM Lee B1, Garay OU2, Goldhaber-Fiebert J3, Wilson LS1, 1University of California, San Francisco, San Francisco, CA, USA, 2Institute for Clinical Effectiveness and

Health Policy (IECS), Buenos Aires, Argentina, 3Stanford University, Stanford, CA, USA


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21RISK MANAGEMENT STUDIES Bayside BC (4th Floor)Moderator: Sheryl L. Szeinbach, PhD, RPh, MS, Professor, College of Pharmacy, Ohio State University, Columbus, OH, USApgA11 RM1 PATIENT AND PHYSICIAN PREFERENCES IN THE UNITED STATES FOR BENEFITS AND RISKS OF ANTICOAGULANT USE IN ATRIAL FIBRILLATION – 2:15PM-2:30PM RESULTS FROM A CONJOINT-ANALYSIS STUDY Levitan B1, Yuan Z1, González JM2, Hauber AB2, Lees M3, Piccini JP4, Singer DE5, Nessel C6, 1Janssen Research & Development, Titusville, NJ, USA, 2RTI Health

Solutions, Research Triangle Park, NC, USA, 3Bristol-Myers Squibb, Rueil-Malmaison, France, 4Duke University Medical Center, Durham, NC, USA, 5Harvard Medical School, Boston, MA, USA, 6Janssen Research & Development, Raritan, NJ, USA

pgA11 RM2 USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS, AND RISK OF DEMENTIA IN HEART FAILURE2:30PM-2:45PM Chitnis AS1, Johnson ML2, Aparasu RR2, Chen H2, Kunik ME3, Schulz PE4, 1United BioSource Corporation, Lexington, MA, USA, 2University of Houston, Houston,

TX, USA, 3Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Houston, TX, USA, 4The University of Texas Health Science Center at Houston, Houston, TX, USA

pgA11 RM3 SULFONYLUREAS ARE ASSOCIATED WITH ELEVATED RISK OF HIP FRACTURES AMONG ELDERLY MEN AND WOMEN WITH TYPE-2 DIABETES2:45PM-3:00PM Rajpathak SN1, Fu C1, Engel SS1, Brodovicz KG1, Lapane K2, 1Merck & Co, North Wales, PA, USA, 2University of Massachussets, Worcester, MA, USApgA12 RM4 EXTERNAL VALIDATION OF THE RISK-PREDICTION MODEL FOR HEPATOCELLULAR CARCINOMA [HCC] FROM THE REVEAL HCV STUDY3:00PM-3:15PM Matsuda T1, Tonnu-Mihara I2, Yuan Y3, Hines P3, Saab S4, LItalien GJ5, McCombs J1, 1University of Southern California, Los Angeles, CA, USA, 2VA Long Beach,

Long Beach, CA, USA, 3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 5Bristol Myers Squibb, Wallingford, CT, USA

SELECTION BIAS STUDIES Nottoway (4th Floor)Moderator: Onur Baser, PhD, MS, MA, President, STATinMED and Adjunct Professor of Internal Medicine, University of Michigan, Ann Arbor, MI, USApgA12 SB1 BURDEN OF SCHIZOPHRENIA ON SELECTED COMORBIDITIES COSTS2:15PM-2:30PM Lafeuille MH1, Dean J2, Fastenau J3, Panish JM3, Olson WH3, Markowitz M3, Duh MS2, Lefebvre P1, 1Groupe d’analyse, Ltée, Montréal, QC, Canada, 2Analysis

Group, Inc., Boston, MA, USA, 3Janssen Scientific Affairs, LLC, Titusville, NJ, USApgA12 SB2 MEDICAL, DRUG, AND WORK-LOSS COSTS OF DIABETIC FOOT ULCERS2:30PM-2:45PM Rice JB1, Desai U1, Cummings AK1, Birnbaum HG1, Skornicki M2, Parsons N2, 1Analysis Group, Inc., Boston, MA, USA, 2Organogenesis Inc., Canton, MA, USApgA12 SB3 THE PREVALENCE OF OPIOID-RELATED MAJOR POTENTIAL DRUG-DRUG INTERACTIONS AND THEIR IMPACT ON HEALTH CARE COSTS2:45PM-3:00PM Summers K1, Pergolizzi J2, Ma L1, Foster D3, Overholser B3, Sowinski K3, 1Endo Pharmaceuticals, Inc., Malvern, PA, USA, 2Johns Hopkins University, Naples, FL,

USA, 3Purdue University College of Pharmacy, Indianapolis, IN, USApgA12 SB4 TIME-SPECIFIC PROPENSITY SCORE ANALYSIS FOR OBSERVATIONAL STUDY: A CASE STUDY ESTIMATING THE EFFECTIVENESS OF THIAZOLIDINEDIONE 3:00PM-3:15PM USE Dilokthornsakul P1, Chaiyakunapruk N1, Lee T2, 1Center of Pharmaceutical Outcomes Research, Naresuan University, Muang, Phitsanulok, Thailand, 2University

of Illinois at Chicago, Chicago, IL, USA

3:15PM-3:45PM BREAK & EXHIBITS VIEWING 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by STATinMED ResearchCookies sponsored by RTI Health Solutions

3:45PM-7:45PM RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV Napoleon Ballroom (3rd Floor)

3:45PM-4:45PM WORKSHOPS - SESSION II

ECONOMIC OUTCOMES RESEARCHW8: ANIMATION OF DISCRETE EVENT SIMULATION MODELS: POWERFUL GOOD MODELING PRACTICE FOR VALIDATION, UNDERSTANDING, AND REPORTING Nottoway (4th Floor)Discussion Leaders: Jorgen Moller, MSc, Vice President, Health Economic Modeling, United BioSource Corporation, Eslov, Sweden; Luis Hernandez, MSc, Research Associate, United BioSource Corporation, Lexington, MA, USA; Jay Patrick Bae, PhD, Principal Research Scientist, Global Health Outcomes, Eli Lilly & Company, Indianapolis, IN, USA

W9: ACCOUNTING FOR HETEROGENEITY, TEMPORAL UNCERTAINTY, AND IMPLEMENTATION IN UNCERTAINTY ASSESSMENT FOR HEALTH CARE DECISION MAKING Bayside BC (4th Floor)Discussion Leaders: Susan Griffin, PhD, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Manuel Antonio Espinoza, MD, MSc, PhD, Scientific Advisor, Health Technology Assessment, Institute of Public Health, Santiago, Chile; Ronan Mahon, MSc, PhD Student, Centre for Health Economics, University of York, York, North Yorkshire, UK; Ties Hoomans, PhD, Assistant Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCHW10: VALUE-BASED PRICING: GETTING IT RIGHT FOR PEOPLE WITH CANCER Grand Ballroom AB (5th Floor)Discussion Leaders: Jacque Anne Mallender, MSc, Director, Matrix Knowledge, London, UK; Carole Anne Jones, MBA, Head of Pharmaceutical Advisory, Matrix Knowledge, London, UK; Alexis Wieroniey, BA (Hons), Senior Campaigns Officer, Prostate Cancer UK, London, UK


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCHW11: MEASURING PATIENT-REPORTED OUTCOMES IN RARE DISEASES Grand Ballroom DE (5th Floor)Discussion Leaders: Katy Benjamin, PhD, Director, Patient-Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Bethesda, MD, USA; Andrew J. Lloyd, DPhil, Vice President, Patient-Reported Outcomes, Oxford Outcomes Ltd., an ICON PLC Company, Oxford, Oxon, UK; Anne Pariser, MD, Associate Director for Rare Diseases, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA; Rahul Sasane, PhD, Global Market Access Strategy Lead – Hematology, Bayer Pharmaceuticals, Montville, NJ, USA

W12: DISCRETE-CHOICE EXPERIMENTS AND BEST-WORST SCALING: EMPIRICAL AND METHODOLOGICAL DIFFERENCES AND DOES CHOICE MATTER? Grand Ballroom C (5th Floor) Discussion Leaders: F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Asso-ciate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada; Joris D. van Dijk, BSc, Student, Health Technology and Services Research, University of Twente, Enschede, The Netherlands; Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands

USE OF REAL WORLD DATAW13: IDENTIFYING HIGH RISK OR HIGH VALUE PATIENT COHORTS: OVERVIEW OF METHODS AND APPLICATIONS OF PATIENT PHENOTYPING ANALYSES Bayside A (4th Floor)Discussion Leaders: Howard Friedman, MS, PhD, Senior Partner, DataMed Solutions LLC, New York, NY, USA; Patrick Sullivan, PhD, MA, Associate Professor, School of Pharmacy, Regis University, Denver, CO, USA; Kristijan Kahler, PhD, RPh, Head, Outcomes Evidence & Analytics, Global Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

W14: USING ELECTRONIC MEDICAL RECORD (EMR) DATA FOR CONDUCTING RETROSPECTIVE STUDIES: OPPORTUNITIES AND PITFALLS Oak Alley (4th Floor)Discussion Leaders: Natalia Olchanski, MS, Project Director, Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Pei-Jung Lin, PhD, Assistant Professor, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Kathy Lang, PhD, Senior Director, Boston Health Economics, Inc., Waltham, MA, USA; Aaron Winn, MPP, Research Associate II, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

5:00PM-6:00PM WORKSHOPS - SESSION III

CLINICAL OUTCOMES RESEARCHW15: INCORPORATING PATIENT LEVEL DATA IN A NETWORK META-ANALYSIS Grand Ballroom C (5th Floor)Discussion Leaders: Jeroen P. Jansen, PhD, Vice President, Health Economics & Outcomes Research, MAPI Consultancy/Tufts University School of Medicine, Boston, MA, USA; Gorana Capkun-Niggli, PhD, Director, Global HE&OR, Novartis Pharma AG, Basel, Switzerland; Shannon Cope, MSc, Senior Research Manager, MAPI Consultancy, Boston, MA, USA

ECONOMIC OUTCOMES RESEARCHW16: SEQUENTIAL DECISION MODELING WITH MARKOV DECISION PROCESSES Bayside A (4th Floor)Discussion Leaders: Jagpreet Chhatwal, PhD, Assistant Professor, Health Policy and Management, University of Pittsburgh, Pittsburgh, PA, USA; Oguzhan Alagoz, PhD, Associate Professor, Industrial Engineering, University of Wisconsin-Madison, Madison, WI, USA

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCHW17: ONE SIZE DOES NOT FIT ALL: HOW TRADITIONAL PRICING AND REIMBURSEMENT POLICIES AFFECT ORPHAN DISEASE THERAPY Grand Ballroom AB (5th Floor)Discussion Leaders: Cyrus A. Chowdhury, MS, Chief Executive Officer, CBPartners, New York City, NY, USA; Corinna Sorenson, MPH, MHSA, Research Fellow in Health Policy, Health & Social Care, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK; Rachel Beckerman, PhD, Principal, Value Demonstration, CBPartners, New York, NY, USA; Mónica Martín de Bustamante, AB, BE, Managing Director, Europe, Middle East, and Africa, CBPartners, Basel, Switzerland

W18: ONE OF THESE PATIENTS IS NOT LIKE THE OTHERS: DEVELOPMENT AND APPLICATION OF A TOOL FOR HEALTH CARE DECISION MAKERS TO ASSESS AND CONSIDER HETEROGENEITY IN COVERAGE DECISIONS Bayside BC (4th Floor)Discussion Leaders: Jennifer S. Graff, PharmD, Director, Comparative Effectiveness Research, National Pharmaceutical Council, Washington, DC, USA; Karen Van Nuys, PhD, Senior Research Economist, Precision Health Economics, Los Angeles, CA, USA; Michael X. West, PhD, Senior Payer Medical Science Liaison, GlaxoSmithKline, Research Triangle, NC, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCHW19: THE UTILITY OF MIXED-METHOD APPROACHES TO EVALUATE THE CONTENT VALIDITY OF PRO MEASURES Nottoway (4th Floor)Discussion Leaders: William R. Lenderking, PhD, Senior Research Leader, United BioSource Corporation, Lexington, MA, USA; Cheryl Coon, PhD, Director, Psychometrics, RTI Health Solutions, Research Triangle Park, NC, USA; Sheri E. Fehnel, PhD, Vice President, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA; Laurie B. Burke, RPh, MPH, Director, Study Endpoints and Labeling Development, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

W20: PATIENTS MATTER – ENGAGING PATIENTS AS COLLABORATORS TO IMPROVE HEALTH CARE PLANNING, HEALTH SERVICE DELIVERY, AND SELF-CARE Grand Ballroom DE (5th Floor)Discussion Leaders: Durhane Wong-Rieger, PhD, Chair, International Alliance of Patients’ Outcomes, Toronto, ON, Canada; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada; Tracy Wasylak, MSc, CHE, Vice President, Strategic Clinical Networks & Clinical Care Pathways, Al-berta Health Services, Calgary, AB, Canada; Nancy J. Marlett, PhD, Associate Professor, Community Rehabilitation and Disability Studies Community Health Sciences, University of Calgary, Calgary, AB, Canada

USE OF REAL WORLD DATAW21: WHAT’S IN A CLAIM? UNDERSTANDING THE SOURCES AND COMPONENTS OF ADMINISTRATIVE CLAIMS DATA Oak Alley (4th Floor)Discussion Leaders: Aylin Riedel, PhD, Vice President, OptumInsight, Eden Prairie, MN, USA; Henry Henk, PhD, Senior Fellow, OptumInsight, Eden Prairie, MN, USA; Donna L. Spencer, PhD, Senior Research Associate, School of Public Health, University of Minnesota, Minneapolis, MN, USA

6:00PM-7:45PM EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION IV 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Reception sponsored by Kantar Health

6:15PM-7:15PM ISPOR FORUMS - SESSION II

MEET THE EDITORS OF VALUE IN HEALTH Grand Ballroom C (5th Floor)This forum will provide attendees with the opportunity to meet with the editors of Value in Health. Session topics include: What makes a great paper? How will my paper be reviewed? How can I volunteer to be a reviewer for Value in Health? The editors will also be on hand to answer any other questions you may have about publishing in Value in Health. Presented by the Co-Editors-in-Chief of Value in HealthModerators & Speakers: Michael Drummond, PhD, Co-Editor-in-Chief, Value in Health and Professor of Health Economics, Centre for Health Economics, University of York, Hes-lington, York, UK; C. Daniel Mullins, PhD, Co-Editor-in-Chief, Value in Health and Professor, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USASpeakers: Several Co-Editors of Value in Health will also participate in the discussion.

USING MIXED MODES TO CAPTURE PATIENT-REPORTED OUTCOMES DATA IN CLINICAL TRIALS Oak Alley (4th Floor)Using different modes of data collection (e.g. paper and handheld device; IVR and Web) within clinical trials does occur. Task Force recommendations regarding issues of measurement equivalence, migration, data quality, and comparability, as well as analytical approaches for pooling of data, will be discussed. Presented by the ISPOR PRO Mixed Modes Good Research Practices Task Force Moderator & Speaker: Sonya Eremenco, MA, Chair, ISPOR PRO Task Force: Good Research Practices for Mixed Modes to Collect PRO Data in Clinical Trials and ePRO Manager, United BioSource Corporation, Bethesda, MD, USA Speakers: Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA; Jean Paty, PhD, Chief Scientist and Regulatory Advisor - Outcomes, ERT, Inc., Pittsburgh, PA, USA

MARKET ACCESS CHALLENGES FOR IN VITRO DIAGNOSTIC: SIMILARITIES AND DIFFERENCES BETWEEN THE US AND EUROPEAN MARKETS Grand Ballroom AB (5th Floor)Global policies and expectations related to medical device and diagnostic technologies are evolving rapidly. This forum will provide detailed insights from the United States and Europe on similarities and differences in market access processes for in vitro diagnostics. The discussion will focus on payer and health technology assessments (HTA) evidence requirement differences, evolving HTA methodologies, and current challenges for evidence generation. Emerging challenges to achieving pricing and reimbursement given the rapidly changing technologies, such as next generation sequencing, and evolving coding systems will be highlighted. Real-world examples of recent HTA for companion and high-value diagnostics in the United States and in Europe will be presented, as well as an overview of the molecular pathology coding and gap filling process in the United States, as it represents a “game changer” with regards to how laboratory developed tests versus FDA-approved tests are evaluated and paid-for. Presented by the ISPOR HTA Special Interest GroupModerator: Susan Garfield, DrPH, Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA Speakers: Michael Longacre, BSc, Reimbursement Director, Corporate/Shared Services, Becton Dickenson, Washington, DC, USA; Nick Poulios, PhD, Head, Medical Outcomes – Reimbursement & Economics, Roche Molecular Systems, Pleasanton, CA, USA; Eric Faulkner, MPH, Director, Global Market Access, Quintiles, Durham, NC, USA

PRICING OF PHARMACEUTICALS IN EMERGING COUNTRIES OF THE CENTRAL & EASTERN EUROPEAN REGION Grand Ballroom DE (5th Floor)Control of drug prices is one of the most important tools for pharmaceutical cost-containment policies. Policymakers pay attention to decisions and price control mechanisms in other countries. Therefore pricing policy decisions in one country may influence policy decisions and consequently health benefits of patients in other countries. This forum will discuss how the pharmaceutical price arsenal is applied in some emerging countries of Central and Eastern Europe. Preliminary findings of a Central and Eastern European policy survey on the implications of international pharmaceutical price referencing will also be presented. Presented by the ISPOR Central & Eastern Europe NetworkModerator & Speaker: Zoltán Kaló, MD, MSc, PhD, Director, Health Economics Research Centre, Eötvös Loránd University (ELTE), Syreon Research Institute, Budapest, HungarySpeakers: Vitaly V. Omelianovskiy, MD, PhD, President, ISPOR HTA Russia Chapter and Professor & Chairman of the Board, National Center for Technology Assessment in Health Care; Deputy Director, Center for Monitoring and Clinical & Economic Evaluation Organization, National Center for Health Technology Assessment, Moscow, Russia; Joanna Lis, MSc, PhD, President, ISPOR Poland Chapter; Adjunct Professor, Pharmacoeconomics Department, Medical University of Warsaw; Director, Public Affairs and Market Access, Sanofi Poland, Warsaw, Poland; Vlad Zah, PhD (c) and Health Economics Consultant, Belgrade, Serbia; Olga Zaliska, PhD, Dr.Sci (Pharm), President, ISPOR Ukraine Chapter and Professor, Department of Organization & Economy of Pharmacy and Medicine Technology, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

IMPROVING HEALTH CARE EQUALITY IN RUSSIA Bayside BC (4th Floor)(Presented in Russian with slides in English) This forum will review recent initiatives of the ISPOR Russia Chapter during its 15 years “on the road,” protecting and improving equality in health care in Russia. Representatives from the ISPOR Russia Chapter, the HTA Institute, and the Eurasian Alliance of Pharmacoeconomics Societies will describe their scientific, educational, and policy related activi-ties during the last 15 years. Presented by the ISPOR Russia Regional Chapter


PROGRAM AND SCHEDULE OF EVENTS: TUESDAY, MAY 21 & WEDNESDAY, MAY 22Moderator: Pavel A. Vorobiev, MD, PhD, MS, President, ISPOR Russia Regional Chapter, Professor & Head, Department of Hematology and Geriatrics and Faculty, Postgraduate Medical Education, First Sechenov Moscow State Medical University, Moscow, RussiaSpeakers: Liubov Krasnova, MD, PhD, Senior Researcher, Department of Hematology and Geriatrics, First Sechenov Moscow Medical University, Moscow, Russia; Lyudmila Bezmelnitsina, MD, Faculty, Postgraduate Medical Education, First Sechenov Moscow Medical University, Moscow, Russia; Malwina Holownia, MPharm, Head, Department of Economics, First Sechenov Moscow Medical University, Moscow, Russia

ECONOMIC ASSESSMENT IN AFRICA: DEVELOPMENT OF HEALTH ECONOMIC EVALUATION REPORTING Nottoway (4th Floor)Health technology assessments that encompass economic evaluations are essential to the efficiency and sustainability of every health care system. With the differences in health costs and clinical care practice between countries, investments in health economics and development of economic evaluation guidelines help to make better decisions. Improving the quality and uniformity of economic evaluations reporting increases its value to decision makers. This forum will provide an overview of the development of health economic evaluation reporting in African countries. The presentation will provide a platform to discuss commonalities as well as differences and specific issues related to economic evalu-ation and its role in the cost-effectiveness of health care delivery in Africa. A country-specific analysis will be provided from speakers representing: Egypt, Ghana, Nigeria, and South Africa. Presented by the ISPOR Egypt, Ghana, Nigeria, and South Africa Regional ChaptersModerator & Speaker: Jacques Snyman, MBChB, MPharm Med, MD, President, ISPOR South Africa Chapter and Clinical Pharmacologist, Agility Global Health Solutions, Pretoria, South AfricaSpeakers: Manal El-Hamamsy, BSPharm, PhD, Assistant Professor, Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt; Peter Agyei-Baffour, PhD, Health Economics Lecturer, Community Health Department, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; Anthony Waka Udezi, PhD, Department of Clinical Pharmacy, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

THE ROLE OF HTA IN THE BRAZILIAN PRICING & REIMBURSEMENT PROCESS: LESSONS LEARNED AND CHALLENGES AHEAD Bayside A (4th Floor)Pricing and reimbursement are real challenges for anyone who wants to achieve success in the Brazilian market, currently one of the largest markets in the word. This forum will discuss how HTA, a mandatory step in the pricing and reimbursement process, came about in the Brazilian market, changed the local landscape, and the resulting issues that arose. Future trends will also be discussed from the local perspective. Presented by the ISPOR Brazil Regional ChapterModerator: Stephen Doral Stefani, MD, Medical Auditor, Head of Oncology Unit, UNIMED, Porto Alegre, BrazilSpeakers: Gabriela Tannus, MBA, MSc, Owner & Health Economics Director, Axia.Bio Consulting, São Paulo, Brazil; Marcelo Fonseca, MD, MSc, Professor, Health Technology Assessment and Clinical Research, Federal University of São Paulo (UNIFESP), Director, Axia.Bio, Pediatrician, Private Practice, and Assistant Physician, Pediatric Intensive Care Unit, University of São Paulo Faculty of Medicine Clinics Hospital, São Paulo, Brazil; Clarice Petramale, MD, Director, Unified Health System (SUS), Brazilian Ministry of Health, Brasilia, Brazil; Flávia Elias, MBA, MSc, Coordinator General, HTA Unit, Department of Science and Technology (DECIT), Brazilian Ministry of Health and Coordinator of the Executive Committee, Brazilian HTA Network (REBRATS), Brasilia, Brazil

6:45PM-7:45PM POSTER AUTHOR DISCUSSION HOUR - SESSION IV Napoleon Ballroom (3rd Floor)

8:00PM-11:30PM ISPOR SOCIAL EVENT House of BluesJoin colleagues for an enjoyable evening of live music, dancing, dinner, and drinks at the House of Blues, located in the historic French Quarter! (Seating is casual with limited seats)Approximately a 5 minute walk from the Sheraton New Orleans to the House of Blues!To register: Please see ISPOR Registration, onsite registration is subject to availability.

WEDNESDAY, MAY 22

8:30AM-2:45PM RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V Napoleon Ballroom (3rd Floor)

8:30AM-9:30AM ISSUE PANELS - SESSION III

ECONOMIC OUTCOMES RESEARCH ISSUESIP11: WHOSE PERSPECTIVE SHOULD DETERMINE THE VALUE OF PERSONALIZED MEDICINE – THE PATIENT, THE PHYSICIAN, OR SOCIETY? Nottoway (4th Floor)Moderator: Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands Panelists: F. Reed Johnson, PhD, Distinguished Fellow & Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada; Kathryn Phillips, PhD, Professor, Center for Translational and Policy Research on Personalized Medicine (TRANSPERS), Department of Clinical Pharmacy, University of California, San Francisco, San Francisco, CA, USA

Featuring the ISPOR

Monte Carlos Band


PROGRAM AND SCHEDULE OF EVENTS: WEDNESDAY, MAY 22HEALTH POLICY DEVELOPMENT USING OUTCOMES RESEARCH ISSUESIP12: SETTING PRIORITIES IN RESEARCH: DOES VALUE OF INFORMATION ANALYSIS HAVE A ROLE? Grand Ballroom DE (5th Floor)Moderator: Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK Panelists: Susan Griffin, PhD, Senior Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK; Scott Ramsey, PhD, MD, Member, Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA; Rachael Fleurence, PhD, Director, Patient-Centered Outcomes Research Insitute (PCORI), Washington, DC, USA

IP13: PRESCRIPTION DRUG MONITORING PROGRAMS: ARE WE WALKING THE TIGHTROPE BETWEEN CONTROLLED SUBSTANCE ACCESS AND ABUSE? Oak Alley (4th Floor)Moderator: Patricia R. Freeman, PhD, Clinical Associate Professor, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA Panelists: Cheryl Anderson, BSPharm, Director, South Carolina Prescription Monitoring Program and President, Alliance of States with Prescription Monitoring Programs, Bureau of Drug Control, South Carolina Department of Health and Environmental Control, Columbia, SC, USA; Bob Twillman, PhD, FAPM, Director of Policy and Advocacy, American Academy of Pain Management, Lenexa, KS, USA; Jeffery Talbert, PhD, Associate Professor & Director, Institute for Pharmaceutical Outcomes and Policy, University of Kentucky, Lexington, KY, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCH ISSUESIP14: WHAT ARE THE EMERGING STANDARDS, BARRIERS, AND SOLUTIONS FOR PATIENT-REPORTED OUTCOMES IN PERFORMANCE EVALUATION AND QUALITY IMPROVEMENT? Bayside (4th Floor)Moderator: Ethan Basch, MD, MSc, Director, Cancer Outcomes Research Program, University of North Carolina, Chapel Hill, NC, USA Panelists: Karen Beckman Pace, PhD, MSN, Senior Director, Performance Measures, National Quality Forum, Washington, DC, USA; Phyllis Torda, PhD, Vice President of Strategic and Quality Solutions Group, National Committee for Quality Assurance (NCQA), Washington, DC, USA; Collette Pitzen, RN, BSN, CPHQ, Clinical Measure Development Manager, MM Community Measurement, Minneapolis, MN, USA

IP15: CAN WE USE SOCIAL MEDIA TO SUPPORT CONTENT VALIDITY OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN MEDICAL PRODUCT DEVELOPMENT? Grand Ballroom ABC (5th Floor)Moderator: Margaret Rothman, PhD, Senior Director, PRO Group, GSM&MA, Janssen Global Services, Washington, GA, USA Panelists: Ari Gnanaskathy, MSc, MBA, Head, Patient Reported Outcomes, Patient Reported Outcomes, Novartis Pharmaceutical Corp, East Hanover, NJ, USA; Paul Wicks, PhD, R&D Director, PatientsLikeMe, Cambridge, MA, USA; Elektra Papadopoulos, MD, MPH, Endpoints Reviewer, Study Endpoints and Labeling Development, Office of New Drugs, CDER, U.S. Food and Drug Administration, Silver Spring, MD, USA

9:30AM-9:45AM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by Medaxial Cookies sponsored by Truven Health Analytics

9:45AM-11:00AM WELCOME & THIRD PLENARY SESSION Grand Ballroom ABC (5th Floor)

WELCOMEDeborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

THIRD PLENARY SESSION: ASSESSING THE EVIDENCE FOR THE HEALTH CARE DECISION MAKERISPOR, as part of the AMCP/ISPOR/NPC Comparative Effectiveness Collaboration Initiative, has developed questionnaires to help health care decision makers assess and effec-tively use available data, with the goal of improving evidence-based health care decision making and ultimately improving patient health. The questionnaires focus on ‘relevance’ and ‘credibility’ when assessing the evidence from prospective and retrospective observational studies, as well as modeling and indirect treatment comparison evidence synthesis studies. These educational questionnaires help users in reviewing evidence and provide information and assistance in the review and effective use of the information. To enhance the functionality and accessibility, ISPOR has developed an interactive version for these four types of studies. During this session, the elements of the interactive questionnaires, as well as their use by health care decision makers for better patient care, will be presented.Moderator: Joseph C. Cappelleri, PhD, MS, MPH, Senior Director, Pfizer, Inc., Groton, CT, USA

ASSESSING PROSPECTIVE OBSERVATIONAL STUDIES FOR HEALTH CARE DECISIONSSpeaker: Marc Berger, MD, Vice President, Real World Data and Analytics, Pfizer, Inc., New York, NY, USA

ASSESSING RETROSPECTIVE OBSERVATIONAL STUDIES FOR HEALTH CARE DECISIONSSpeaker: Bradley Martin, PhD, Professor & Division Chair, University of Arkansas for Medical Sciences, College of Pharmacy, Department of Pharmacy Practice, Little Rock, AR, USA

ASSESSING INDIRECT TREATMENT STUDIES FOR HEALTH CARE DECISIONSSpeaker: Jeroen Jansen, PhD, Vice President, Health Economics & Outcomes Research, MAPI Consultancy, Boston, MA, USA JansenMartinBerger

Cappelleri

Marshall


PROGRAM AND SCHEDULE OF EVENTS: WEDNESDAY, MAY 22ASSESSING MODELING STUDIES FOR HEALTH CARE DECISIONSSpeaker: J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine & Adjunct Professor of Epidemiology and Biostatis-tics, McGill University, Montreal, QC, Canada

A USER’S PERSPECTIVE ON ASSESSING OBSERVATIONAL, INDIRECT TREATMENT, AND MODELING STUDIESAMCP Speaker: Karen Worley, PhD, Research Leader, Comprehensive Health Insights, Humana, Inc., Cincinnati, OH, USA AMCP Speaker: Sherry Andes, PharmD, Drug Intelligence Supervisor, Catamaran, Lisle, IL, USA

11:00AM-11:30AM ISPOR 18th ANNUAL INTERNATIONAL MEETING RESEARCH PRESENTATION & SERVICE AWARDS Grand Ballroom ABC (5th Floor)

ISPOR SERVICE AND DISTINGUISHED SERVICE AWARDSPresented by: Deborah Marshall, PhD, MHSA, 2012-2013 ISPOR President, Canada Research Chair, Health Services and Systems Research, Arthur J.E. Child Chair in Rheumatology Health Outcomes Research, and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

ISPOR STUDENT AWARDSPresented by: Zeba M. Khan, PhD, RPh, ISPOR Student Network Advisor & Vice President, Pricing & Market Access, Celgene Corporation, Summit, NJ, USA

ISPOR BEST PODIUM PRESENTATIONSPresented by: Onur Baser, PhD, MS, MA, President, STATinMED and Adjunct Professor of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

ISPOR BEST POSTER PRESENTATIONSPresented by: Jeff J. Guo, PhD, Professor, Division of Pharmacy Practice & Administrative Sciences, University of Cincinnati Medical Center College of Pharmacy, Cincinnati, OH, USA

PhRMA FOUNDATION 2013 AWARDSPresented by: Jean Paul Gagnon, PhD, Chairman, PhRMA Foundation Health Outcomes and CER Advisory Committees, Washington, DC, USA

11:30AM-1:45PM LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Lunch sponsored by FACIT.org/FACITtrans

11:45AM-12:45PM EDUCATIONAL SYMPOSIUM Grand Ballroom DE (5th Floor)

FAST ACCESS TO BIG NATIONAL HEALTH CARE DATA SETSSponsored by CPRD

12:45PM-1:45PM POSTER AUTHOR DISCUSSION HOUR - SESSION V Napoleon Ballroom (3rd Floor)

1:45PM-2:45PM WORKSHOPS - SESSION IV

ECONOMIC OUTCOMES RESEARCHW22: MODELS IN THE CLOUD - IMPROVING THE APPLICATION OF ECONOMIC MODELS WITH DYNAMIC DATA ANALYTICS AND A WEB-BASED GRAPHICAL USER INTERFACE Nottoway (4th Floor)Discussion Leaders: Mei Xue, MBA, Senior Analyst, Pharmerit International, Bethesda, MD, USA; Cindy (Xin) Gao, PhD, Director, Health Economics, Pharmerit North America, LLC, Bethesda, MD, USA; Gijs Hubben, PhD, CEO, BaseCase Software, Berlin, Germany; Prabashni Reddy, PharmD, Director, Center for Drug Policy Partners Healthcare, Needham, MA, USA

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCHW23: IMPROVING MEDICARE STAR RATINGS: EVIDENCE IN SUPPORT OF THE USE OF PATIENT MEDICATION ADHERENCE PACKAGING AS AN EFFECTIVE AND MEASURABLE ADHERENCE INTERVENTION Grand Ballroom ABC (5th Floor)Discussion Leaders: Carolyn Harley, PhD, MPA, Director, Market Access, Value Strategy and Health Policy, OptumInsight Life Sciences, Palo Alto, CA, USA; Cyndi Goss, MBA, MPM, Director, Market Access, Value Strategy and Health Policy, OptumInsight Life Sciences, Glen Allen, VA, USA; Elizabeth Whalley Buono, RN, MBA, JD, Vice President, Global Quality, Regulatory & External Affairs, MWV Healthcare, Richmond, VA, USA; Barbara K. Zedler, MD, Chief Medical Officer, Venebio Group, LLC, Richmond, VA, USA

W24: NOVEL APPROACHES IN EARLY PLANNING FOR RELEVANT EVIDENCE GENERATION TO SUPPORT HEALTH CARE DECISION MAKING Grand Ballroom DE (5th Floor)Discussion Leaders: L. Clark Paramore, MSPH, Senior Research Scientist, Health Economics, United BioSource Corporation, Lexington, MA, USA; Rob Thwaites, MA, Vice President, Health Economics, United BioSource Corporation, London, UK; Floortje E. van Nooten, MSc, Associate Director, HEOR, Astellas, Leiden, The Netherlands; Jan E. Hansen, PhD, DrPH, Vice President, Global Health Outcomes, Allergan, Irvine, CA, USA

Marshall

AndesWorleyCaro


PROGRAM AND SCHEDULE OF EVENTS: WEDNESDAY, MAY 22PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCHW25: CHOICE DEFINES VALUE: NEW APPROACHES TO EVALUATING MULTIPLE TREATMENT ATTRIBUTES AND HEALTH OUTCOMES Oak Alley (4th Floor)Discussion Leaders: Benjamin M. Craig, PhD, Assistant Faculty Member, Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL, USA; Juan Marcos González, PhD, Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Axel Mühlbacher, PhD, MBA, Professor of Health Economics and Health Care Management, IGM Institute Health Economics and Health Care Management, Hochschule Neubrandenburg, Neubrandenburg, Germany

USE OF REAL WORLD DATAW26: EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA Bayside (4th Floor)Discussion Leaders: Daniel M. Huse, MA, Vice President, Truven Health Analytics, Cambridge, MA, USA; Patricia A. Russo, PhD, MSW, RN, Vice President, Integrated Analytic Services, Quintiles, Washington, DC, USA; Joseph Vasey, PhD, Director, Epidemiology, Integrated Analytic Services, Quintiles, Bellefonte, PA, USA; Emily Durden, PhD, Research Leader, Outcomes Research, Truven Health, Austin, TX, USA

2:45PM-3:00PM BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING - SESSION V 2nd Floor (Waterbury, Lagniappe, and Rhythms), 3rd Floor (Napoleon Ballroom) & 5th Floor (Grand Ballroom Lobby)

Coffee sponsored by MedaxialCookies sponsored by Truven Health Analytics

3:00PM-4:00PM WORKSHOPS - SESSION V

ECONOMIC OUTCOMES RESEARCHW27: EVALUATIONS OF TREATMENT PATHWAYS IN ONCOLOGY: CLINICAL AND ECONOMIC CONSIDERATIONS AND MODELING APPROACHES Grand Ballroom ABC (5th Floor)Discussion Leaders: Sonja Sorensen, MPH, Senior Research Scientist, United BioSource Corporation, Bethesda, MD, USA; Feng Pan, PhD, Research Scientist, Health Economics, United BioSource Corporation, Bethesda, MD, USA; Jianming He, MS, MA, Associate Director, Janssen Global Services LLC, Raritan, NJ, USA; Kevin Knopf, MD, MPH, Medical Oncologist, California Pacific Medical Center, San Francisco, CA, USA

HEALTH CARE POLICY DEVELOPMENT USING OUTCOMES RESEARCHW28: ADAPTING AMCP FORMAT-BASED DOSSIERS: EVIDENCE GUIDELINES FOR SPECIALTY PHARMACEUTICALS, COMPANION DIAGNOSTICS, AND COMPARATIVE EFFECTIVENESS RESEARCH Oak Alley (4th Floor)Discussion Leaders: Jeff Lee, PharmD, National Director, Regional Scientific Services, Allergan. Inc., Franklin, TN, USA; Bryan R. Luce, PhD, MBA, Chief Science Officer, Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA; Pete Penna, PharmD, President, Formulary Resources, LLC, Mercer Island, WA, USA; David L. Veenstra, PhD, PharmD, Professor, Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA

W29: DON’T FORGET ABOUT THE PATIENT! LISTENING TO PATIENTS AND INVOLVING THEM IN RESEARCH Grand Ballroom DE (5th Floor)Discussion Leaders: Elisa Cascade, MBA, Vice President, Digital Patient Unit, Quintiles, Inc., Rockville, MD, USA; John Doyle, PhD, Senior Vice President, Drug Development Consulting, Quintiles, Inc., Hawthorne, NY, USA; Veronica Todaro, MPH, Director of National Programs, Parkinson’s Disease Foundation (PDF), New York, NY, USA

PATIENT-REPORTED OUTCOMES & PATIENT PREFERENCE RESEARCHW30: DEPLOYING EPRO INSTRUMENTS IN CLINICAL TRIALS: CHALLENGES AND SOLUTIONS Nottoway (4th Floor)Discussion Leaders: Tara Symonds, PhD, Senior Director, Outcomes Research, Pfizer, Inc., Kent, UK; Valdo Arnera, MD, General Manager, Europe, PHT Corporation, Geneva, Switzerland; J. Jason Lundy, PhD, Assistant Director, Patient-Reported Outcome Consortium, Critical Path Institute, Tucson, AZ, USA; Cindy Howry, MS, Principal, ePRO Solutions, Bracket, Austin, TX, USA

USE OF REAL WORLD DATAW31: THE USE OF PATIENT-CENTERED HEALTH CARE INFORMATION FROM SOCIAL NETWORKING SOURCES IN HEALTH ECONOMICS AND OUTCOMES RESEARCH Bayside (4th Floor)Discussion Leaders: Luke Boulanger, MA, MBA, Senior Research Scientist & Senior Director, Health Economics, United BioSource Corporation, Lexington, MA, USA; Doug McClure, MIM, Chief Technology Officer, Healthrageous, Boston, MA, USA; L. Clark Paramore, MSPH, Senior Research Scientist, Health Economics, United BioSource Corporation, Lexington, MA, USA

ISPOR members worldwide are actively participating in ISPOR working groups to advance global health outcomes research and the use of this research in health care decisions. These ISPOR groups provide an opportunity for members to contribute to translating outcomes research to health care decisions. The following is a listing of the ISPOR group meetings being held during the ISPOR 18th Annual International Meeting. Please note that these meetings are by prior invitation only. However, ISPOR encourages your future involvement in ISPOR’s working groups.


ISPOR GROUP MEETINGS (BY INVITATION ONLY)

ISPOR BOARD OF DIRECTORSSUNDAY, MAY 19

11:00AM-3:15PM ISPOR BOARD OF DIRECTORS Southdown (4th Floor)

ISPOR COUNCILS AND ROUNDTABLESSUNDAY, MAY 19

12:00PM-5:00PM ISPOR STUDENT LEADERSHIP RETREAT Armstrong (8th Floor)

MONDAY, MAY 2012:15PM-1:15PM ISPOR INSTITUTIONAL COUNCIL Borgne (3rd Floor)

1:45PM-2:45PM ISPOR INSTITUTIONAL COUNCIL: PERSONALIZED MEDICINE VALUE IN HEALTH SPECIAL ISSUE Gallier A (4th Floor)

TUESDAY, MAY 2112:15PM-1:15PM ISPOR STUDENT COUNCIL & FACULTY ADVISOR Borgne (3rd Floor)

WEDNESDAY, MAY 221:00PM-6:00PM ISPOR 17TH HTA - PHARMACY & THERAPEUTICS ROUNDTABLE Borgne (3rd Floor)

THURSDAY, MAY 239:00AM-12:00PM ISPOR 17TH HTA - PHARMACY & THERAPEUTICS ROUNDTABLE

Borgne (3rd Floor)

ISPOR Council & Roundtable membership is by invitation. For information: www.ispor.org >> Advisory Councils

ISPOR JOURNALS EDITORIAL BOARDS

SUNDAY, MAY 199:45AM-10:45AM ISPOR VALUE IN HEALTH MANAGEMENT ADVISORY BOARD

Southdown (4th Floor)

6:30PM-7:15PM ISPOR VIHRI ASIA EDITORIAL BOARD & EDITORIAL ADVISORY BOARD Southdown (4th Floor)

MONDAY, MAY 207:15AM-8:15AM ISPOR CONNECTIONS EDITORIAL BOARD Gallier A (4th Floor)

12:15PM-1:15PM ISPOR VIHRI CEEWAA EDITORIAL BOARD Estherwood (4th Floor)

5:00PM-7:00PM ISPOR VIHRI LATIN AMERICA EDITORIAL BOARD & EDITORIAL ADVISORY BOARD Gallier A (4th Floor)

7:30PM-9:30PM ISPOR VALUE IN HEALTH EDITORIAL BOARD & EDITORIAL ADVISORY BOARD Southdown (4th Floor)

TUESDAY, MAY 217:15AM-8:15AM ISPOR VIHRI EDITORIAL BOARD Gallier A (4th Floor)

ISPOR Editorial Board membership is by invitation. For information: www.ispor.org >> Publications

ISPOR SPECIAL INTEREST GROUPS (SIG) & TASK FORCES

SATURDAY, MAY 1810:00AM-4:00PM ISPOR CLINICIAN-REPORTED OUTCOMES (ClinROs) GOOD

MEASUREMENT PRACTICES TASK FORCE Ellendale (4th Floor)

6:00PM-9:00PM ISPOR BUDGET IMPACT ANALYSIS GOOD PRACTICES II TASK FORCE Ellendale (4th Floor)

SUNDAY, MAY 198:00AM-4:30PM ISPOR BUDGET IMPACT ANALYSIS GOOD PRACTICES II TASK FORCE

Ellendale (4th Floor)

MONDAY, MAY 2010:45AM-12:30PM ISPOR CONJOINT ANALYSIS TASK FORCE Evergreen (4th Floor)

12:15PM-1:15PM ISPOR HTA SIG Gallier A (4th Floor)

TUESDAY, MAY 217:15AM-8:15AM ISPOR RARE DISEASE SIG Gallier B (4th Floor)

TUESDAY, MAY 21 CONTINUED12:15PM-3:15PM ISPOR ASSESSING THE EVIDENCE TASK FORCE CHAIRS

Estherwood (4th Floor)

2:15PM-3:15PM ISPOR HEALTH OUTCOMES METRICS SIG Evergreen (4th Floor)

ISPOR Special Interest Groups (SIGs) and Task Forces develop valuable tools for ISPOR members, the outcomes research community, decision makers and the public. SIG and Task Force Review Group membership is open to all ISPOR members. For information and to join: www.ispor.org >> Interest Groups >> Task Forces

ISPOR REGIONAL CONSORTIA, CHAPTERS, AND NETWORKSSUNDAY, MAY 19

5:15PM-6:15PM ISPOR GHANA & NIGERIA REGIONAL CHAPTERS Oakley (4th Floor)

5:30PM-6:15PM ISPOR ASIA CONSORTIUM EXECUTIVE COMMITTEE Gallier AB (4th Floor)

6:30PM-7:30PM ISPOR JORDAN, QATAR, & UNITED ARAB EMIRATES REGIONAL CHAPTERS Oakley (4th Floor)

MONDAY, MAY 20 7:00AM-8:15AM ISPOR ASIA CONSORTIUM Borgne (3rd Floor)

7:30AM-8:30AM ISPOR EGYPT REGIONAL CHAPTER Gallier B (4th Floor)

12:15PM-1:15PM ISPOR CHICAGO REGIONAL CHAPTER Maurepas (3rd Floor)

12:15PM-1:45PM ISPOR ASIA CONSORTIUM INDUSTRY COMMITTEE Southdown (4th Floor)

1:00PM-2:00PM ISPOR LATIN AMERICA CONSORTIUM ADVISORY COMMITTEE Gallier B (4th Floor)

1:30PM-2:00PM ISPOR ARABIC NETWORK FORUM SPEAKERS Evergreen (4th Floor)

3:00PM-4:00PM ISPOR LATIN AMERICA CONSORTIUM INDUSTRY COMMITTEE LEADERSHIP Evergreen (4th Floor)

3:45PM-4:45PM ISPOR REGIONAL CHAPTERS INFORMATIONAL MEETING: ALGERIA, IRAQ, KENYA, KUWAIT, OMAN, SUDAN, & UGANDA Gallier B (4th Floor)

5:00PM-5:45PM ISPOR CEE NETWORK FORUM SPEAKERS Evergreen (4th Floor)

6:00PM-7:00PM ISPOR LATIN AMERICA CONSORTIUM INDUSTRY COMMITTEE Gallier B (4th Floor)

7:00PM-9:00PM ISPOR LATIN AMERICA CONSORTIUM RECEPTION Maurepas (3rd Floor)

7:00PM-9:00PM ISPOR ASIA CONSORTIUM RECEPTION Borgne (3rd Floor)

TUESDAY, MAY 2112:15PM-1:15PM ISPOR LATIN AMERICA CONSORTIUM EXECUTIVE COMMITTEE Gallier A (4th Floor)

12:15PM-1:30PM ISPOR CENTRAL & EASTERN EUROPE NETWORK Gallier B (4th Floor)

12:15PM-1:45PM ISPOR 6TH ASIA-PACIFIC CONFERENCE COMMITTEE Southdown (4th Floor)

2:00PM-3:00PM ISPOR SAUDI ARABIA REGIONAL CHAPTERS Gallier B (4th Floor)

2:00PM-3:00PM ISPOR RUSSIA HTA & UKRAINE REGIONAL CHAPTERS EXECUTIVE COMMITTEE Gallier A (4th Floor)

4:30PM-5:30PM ISPOR AFRICA REGIONAL CHAPTERS & FORUM SPEAKERS Borgne (3rd Floor)

7:30PM-8:30PM ISPOR ARABIC NETWORK LEADERSHIP Gallier A (4th Floor)

8:30PM-9:30PM ISPOR ARABIC NETWORK RECEPTION Southdown (4th Floor)

WEDNESDAY, MAY 227:15AM-8:15AM ISPOR INDIA NETWORK STEERING COMMITTEE Borgne (3rd Floor)

ISPOR Regional Consortia, Chapters, and Networks encourage the geographical development of pharmacoeconomics and the global flow of ideas and information related to health care decision making. Membership is open to all, based on geographical location/interest.For information and to join: www.ispor.org >>Regional Chapters >> Regional Consortia >> Regional Networks

GET INVOLVED

GET INFORMED

PLEASE NOTE: INVITEES WILL RECEIVE AN EMAIL REMINDER AND NOTIFICATION OF ANY CHANGES TO THIS ISPOR GROUP MEETING SCHEDULE

• Research poster presentations are organized by topic and poster code, please reference the poster layout maps and signage

• Pages 45-121 list the poster titles and authors and give the page number reference to the abstract as published in Value in Health Volume 16, Issue 3 (available near ISPOR registration and online at http://www.ispor.org/valueinhealth_index.asp)

• An Author index is provided in Value in Health Volume 16, Issue 3

• All poster presenters are requested to provide handouts. Research poster presentation abstracts and released poster PDFs are available at the ISPOR Outcomes Research Digest (a searchable database of over 22,000 research papers presented at ISPOR meetings) at http://www.ispor.org/ research_study_digest/index.asp or scan this QR code.

POSTER PRESENTATION SESSIONS POSTER DISPLAY HOURS AUTHOR DISCUSSION HOUR Meet the Author!

SESSION I: Monday, May 20

PRM: RESEARCH ON METHODS 8:30AM-2:15PM 1:15PM-2:15PM

PMH: MENTAL HEALTH

SESSION II: Monday, May 20

PIH: INDIVIDUAL’S HEALTH 3:45PM-7:45PM 6:45PM-7:45PM

PIN: INFECTION

PND: NEUROLOGICAL DISORDERS

PSY: SYSTEMIC DISORDERS/CONDITIONS

SESSION III: Tuesday, May 21

PCN: CANCER 8:30AM-2:15PM 1:15PM-2:15PM

PDB: DIABETES/ENDOCRINE DISORDERS

PSS: SENSORY SYSTEMS DISORDERS

PUK: URINARY/KIDNEY DISORDERS

SESSION IV: Tuesday, May 21

PHS: HEALTH SERVICES 3:45PM-7:45PM 6:45PM-7:45PM

PGI: GASTROINTESTINAL DISORDERS

PMS: MUSCULAR-SKELETAL DISORDERS

PRS: RESPIRATORY-RELATED DISORDERS

SESSION V: Wednesday, May 22

PHP: HEALTH CARE USE & POLICY STUDIES 8:30AM-2:45PM 12:45PM-1:45PM

PCV: CARDIOVASCULAR DISORDERS


RESEARCH POSTER PRESENTATIONS OVERVIEWOver 1,500 poster presentations will be on display during the meeting in the Napoleon Ballroom (3rd Floor)

4TH FLOOROak AlleyNottoway

EllendaleSouth- down

Oakley Gallier Evergreen Estherwood EdgewoodA B

Bayside

Crescent

A B

C

B

A

3RD FLOORMaurepas

Borgne

Napoleon Ballroom

Monday-Wednesday Exhibits & Poster Presentations


MEETING ROOMS FLOOR PLANS

2ND FLOOR

5TH FLOOR

1ST FLOORHotel Main Lobby Gallery

Waterbury

Lagniappe

Rhythms

Grand Chenier Grand

Couteau

Grand Ballroom Lobby

Grand Ballroom

ISPO

R Re

gist

ratio

n

B E

A DC

Speaker Ready Room

Date post:	24-Jan-2017
Category:	Documents
Upload:	vanlien
View:	226 times
Download:	1 times

Meeting Program

Documents